Merck & Co., Inc. (MRK) KPIs and segments
Close on Nov 18, 2026Market cap $339.93BP/E 110.2Yield 2.38%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Merck · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Merck: 118 chỉ số vận hành, trong đó có Keytruda (pembrolizumab, Welireg (belzutifan và Lynparza (olaparib, lấy từ 199 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical($M)37 | 14,760 | 14,349 | 14,843 | 15,611 | 14,050 | 13,638 | 14,042 | 14,943 | 14,408 | 14,006 | 13,141 | 14,263 | |
United States($M) | 8,827 | 8,512 | 8,662 | 9,493 | 8,328 | 7,927 | 7,727 | 8,227 | 7,399 | 6,936 | 6,699 | 7,153 | |
Keytruda($M) | 7,904 | 7,906 | 8,338 | 8,142 | 7,956 | 7,205 | 7,836 | 7,429 | 7,270 | 6,947 | 6,608 | 6,338 | |
Non-US($M) | 5,933 | 5,837 | 6,181 | 6,118 | 5,722 | 5,711 | 6,315 | 6,717 | 7,009 | 7,070 | 6,442 | 7,110 | |
Gardasil/Gardasil 9($M) | 1,169 | 1,069 | 1,031 | 1,749 | 1,126 | 1,327 | 1,551 | 2,306 | 2,478 | 2,249 | 1,871 | 2,585 | |
Other pharmaceutical($M) | 643 | 775 | 649 | 953 | 703 | 865 | 700 | 638 | 618 | 632 | 788 | 568 | |
ProQuad/M-M-R II/Varivax($M) | 592 | 538 | 619 | 684 | 609 | 539 | 594 | 703 | 617 | 570 | 545 | 713 | |
Winrevair($M) | 588 | 525 | 467 | 360 | 336 | 280 | 200 | 149 | 70 | 0 | 0 | 0 | |
Bridion($M) | 497 | 472 | 500 | 439 | 461 | 441 | 449 | 420 | 455 | 440 | 429 | 424 | |
Keytruda Qlex($M) | 463 | 128 | 0 | 0 | |||||||||
Alliance revenue - Lynparza($M) | 365 | 341 | 389 | 379 | 370 | 312 | 364 | 337 | 317 | 292 | 315 | 299 | |
Prevymis($M) | 295 | 272 | 276 | 266 | 228 | 208 | 215 | 208 | 188 | 174 | 175 | 157 | |
Alliance revenue - Lenvima($M) | 283 | 256 | 272 | 258 | 265 | 258 | 255 | 251 | 249 | 255 | 226 | 260 | |
Welireg($M) | 271 | 199 | 220 | 196 | 162 | 137 | 160 | 139 | 126 | 85 | 72 | 54 | |
Januvia($M) | 258 | 367 | 302 | 382 | 372 | 549 | 232 | 278 | 405 | 419 | 547 | 581 | |
Ohtuvayre($M) | 204 | 131 | 0 | 0 | |||||||||
Capvaxive($M) | 184 | 142 | 279 | 244 | 129 | 107 | 50 | 47 | 0 | 0 | |||
Janumet($M) | 171 | 207 | 199 | 243 | 251 | 247 | 256 | 204 | 224 | 251 | 240 | 255 | |
Vaxneuvance($M) | 148 | 202 | 140 | 226 | 229 | 230 | 161 | 239 | 189 | 219 | 177 | 214 | |
RotaTeq($M) | 134 | 206 | 119 | 204 | 121 | 228 | 139 | 193 | 163 | 216 | 185 | 156 | |
Alliance revenue - Adempas/Verquvo($M) | 126 | 109 | 130 | 112 | 123 | 106 | 109 | 102 | 106 | 98 | 108 | 92 | |
Alliance Revenue - Reblozyl($M) | 122 | 148 | 164 | 136 | 107 | 119 | 110 | 100 | 90 | 71 | 70 | 52 | |
Delstrigo($M) | 101 | 75 | 78 | 77 | 83 | 67 | 69 | 65 | 60 | 56 | 53 | 54 | |
Adempas($M) | 78 | 78 | 83 | 82 | 80 | 68 | 73 | 72 | 72 | 70 | 66 | 65 | |
Zerbaxa($M) | 77 | 82 | 87 | 81 | 74 | 70 | 70 | 64 | 62 | 56 | 61 | 53 | |
Isentress/Isentress HD($M) | 60 | 59 | 67 | 82 | 86 | 90 | 92 | 102 | 89 | 111 | 106 | 119 | |
Belsomra($M) | 49 | 47 | 40 | 50 | 45 | 78 | 53 | 46 | 55 | 58 | |||
Pifeltro($M) | 43 | 43 | 41 | 45 | 40 | 42 | 39 | 42 | 33 | 37 | |||
Pneumovax 23($M) | 42 | 45 | 38 | 41 | 75 | 68 | 59 | 61 | 85 | 140 | |||
Dificid($M) | 22 | 34 | 25 | 43 | 96 | 83 | 79 | 96 | 92 | 73 | 87 | 74 | |
Alliance revenue - Koselugo($M) | 10 | 161 | 214 | 43 | 44 | 39 | |||||||
Lagevrio($M) | 5 | 28 | 57 | 138 | 83 | 102 | 121 | 383 | 110 | 350 | 192 | 640 | |
Simponi($M) | 0 | 0 | 0 | 0 | 189 | 172 | 184 | 171 | 179 | ||||
Remicade($M) | 0 | 0 | 0 | 0 | 41 | 35 | 39 | 43 | 45 | ||||
Intl($M) | 7,070 | 6,442 | 7,110 | ||||||||||
Noxafil($M) | 36 | 41 | 45 | 56 | 46 | 51 | |||||||
Primaxin($M) | 39 | 41 | |||||||||||
Vaqta($M) | 29 | 69 | |||||||||||
Animal Health($M)5 | 1,775 | 1,791 | 1,505 | 1,615 | 1,646 | 1,588 | 1,397 | 1,487 | 1,482 | 1,511 | 1,278 | 1,400 | |
Non-US($M) | 1,240 | 1,272 | 1,056 | 1,112 | 1,147 | 1,086 | 953 | 999 | 1,027 | 1,037 | 892 | 938 | |
Livestock($M) | 1,041 | 1,064 | 987 | 1,023 | 961 | 924 | 889 | 886 | 837 | 850 | 807 | 874 | |
Companion Animal($M) | 734 | 727 | 592 | 685 | 664 | 601 | 645 | 661 | 526 | ||||
United States($M) | 535 | 519 | 448 | 504 | 499 | 502 | 444 | 487 | 455 | 474 | 386 | 462 | |
Intl($M) | 1,037 | 892 | 938 | ||||||||||
United States($M) | 9,367 | 9,164 | 9,139 | 10,012 | 8,836 | 8,522 | 8,188 | 8,736 | 7,876 | 7,478 | 7,087 | 7,715 | |
Non-US($M) | 7,173 | 7,109 | 7,237 | 7,230 | 6,869 | 6,797 | 7,268 | 7,716 | 8,036 | 8,107 | 7,334 | 8,048 | |
Europe, Middle East and Africa($M) | 3,920 | 3,886 | 3,791 | 3,680 | 3,659 | 3,454 | 3,380 | 3,583 | 3,515 | 3,563 | 3,276 | 3,327 | |
Latin America($M) | 875 | 874 | 854 | 905 | 859 | 792 | 868 | 936 | 858 | 796 | 788 | 895 | |
Asia Pacific (other than China and Japan)($M) | 820 | 738 | 745 | 764 | 785 | 689 | 764 | 823 | 748 | 724 | 750 | 781 | |
Other($M) | 640 | 679 | 781 | 798 | 595 | 701 | 701 | 624 | 612 | 621 | 599 | 469 | |
Japan($M) | 577 | 555 | 704 | 712 | 626 | 669 | 835 | 938 | 686 | 821 | 650 | 1,081 | |
China($M) | 408 | 390 | 386 | 405 | 446 | 702 | 888 | 1,017 | 1,817 | 1,772 | 1,480 | 1,694 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Pharmaceutical($M) | 13,029 | 12,796 | 13,002 | 13,947 | 12,449 | 12,065 | 12,533 | 13,039 | 12,700 | 12,300 | |||
Animal Health($M) | 1,060 | 1,116 | 824 | 905 | 987 | 988 | 766 | 874 | 870 | 898 | |||
Pharmaceutical($M) | 11,612 | 11,519 | 11,490 | 12,538 | 11,103 | 10,712 | 10,882 | 11,547 | 11,200 | 10,904 | 9,480 | 10,407 | |
Animal Health($M) | 636 | 722 | 394 | 511 | 593 | 634 | 364 | 510 | 508 | 555 | 284 | 421 | |
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M)($M)5 | 7,904 | 7,906 | 8,337 | 8,142 | 7,956 | 7,205 | 7,836 | 7,429 | 7,270 | 6,947 | 6,608 | 6,338 | |
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. sales ($M)($M)1 | 4,611 | 4,599 | 4,892 | 4,879 | 4,749 | 4,308 | 4,841 | 4,500 | 4,412 | 4,119 | 3,972 | 3,795 | |
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. reported growth YoY (%)(%) | -3.0% | 1.0% | 8.0% | 8.0% | 5.0% | 22.0% | 19.0% | 14.0% | 18.0% | 18.0% | 14.0% | ||
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International sales ($M)($M)1 | 3,293 | 3,307 | 3,445 | 3,263 | 3,207 | 2,897 | 2,996 | 2,929 | 2,858 | 2,828 | 2,636 | 2,543 | |
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International reported growth YoY (%)(%) | 3.0% | 15.0% | 11.0% | 12.0% | 2.0% | 14.0% | 15.0% | 19.0% | 22.0% | 27.0% | 21.0% | ||
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%)(%) | -1.0% | 6.0% | 10.0% | 9.0% | 4.0% | 19.0% | 17.0% | 16.0% | 20.0% | 21.0% | 17.0% | ||
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -2.0% | 5.0% | 8.0% | 9.0% | 21.0% | 21.0% | 24.0% | 22.0% | 17.0% | ||||
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M)($M)2 | 463 | 128 | 0 | 0 | |||||||||
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — U.S. sales ($M)($M) | 395 | 106 | 0 | 0 | |||||||||
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — International sales ($M)($M) | 68 | 21 | 0 | 0 | |||||||||
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide sales ($M)($M)4 | 271 | 199 | 220 | 196 | 162 | 137 | 160 | 139 | 126 | 85 | 72 | 54 | |
Welireg (belzutifan — HIF-2α inhibitor) — U.S. sales ($M)($M)1 | 214 | 152 | 181 | 161 | 138 | 123 | 146 | 127 | 116 | 77 | 68 | 51 | |
Welireg (belzutifan — HIF-2α inhibitor) — U.S. reported growth YoY (%)(%) | 55.0% | 24.0% | 27.0% | 19.0% | 59.0% | 114.0% | 148.0% | 138.0% | 89.0% | ||||
Welireg (belzutifan — HIF-2α inhibitor) — International sales ($M)($M) | 57 | 47 | 39 | 35 | 24 | 15 | 14 | 12 | 10 | 7 | 4 | 3 | |
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide reported growth YoY (%)(%) | 67.0% | 37.0% | 42.0% | 29.0% | 62.0% | 122.0% | 156.0% | 150.0% | 102.0% | 79.0% | 43.0% | ||
Welireg (belzutifan — HIF-2α inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 67.0% | 37.0% | 41.0% | 29.0% | 123.0% | 150.0% | 102.0% | 78.0% | 43.0% | ||||
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide sales ($M)($M)4 | 365 | 341 | 389 | 379 | 370 | 312 | 365 | 337 | 317 | 292 | 315 | 299 | |
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. sales ($M)($M)1 | 167 | 149 | 180 | 184 | 174 | 145 | 177 | 161 | 153 | 135 | 168 | 153 | |
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. reported growth YoY (%)(%) | -4.0% | 1.0% | 14.0% | 14.0% | 7.0% | 5.0% | 5.0% | 6.0% | -4.0% | 7.0% | 7.0% | ||
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — International sales ($M)($M)1 | 198 | 192 | 209 | 195 | 195 | 168 | 187 | 177 | 165 | 157 | 147 | 146 | |
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — International reported growth YoY (%)(%) | 2.0% | 12.0% | 11.0% | 19.0% | 7.0% | 28.0% | 21.0% | -1.0% | 18.0% | 9.0% | 4.0% | ||
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide reported growth YoY (%)(%) | -1.0% | 7.0% | 12.0% | 17.0% | 7.0% | 16.0% | 13.0% | 2.0% | 6.0% | 8.0% | 5.0% | ||
Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -2.0% | 4.0% | 12.0% | 15.0% | 18.0% | 4.0% | 7.0% | 8.0% | 6.0% | ||||
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M)($M)4 | 283 | 256 | 272 | 258 | 265 | 258 | 255 | 251 | 249 | 255 | 226 | 260 | |
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. sales ($M)($M)1 | 194 | 176 | 191 | 177 | 183 | 186 | 182 | 173 | 177 | 173 | 181 | 160 | |
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. reported growth YoY (%)(%) | 6.0% | 5.0% | 2.0% | 3.0% | 8.0% | 1.0% | 9.0% | 8.0% | 13.0% | 18.0% | 13.0% | ||
Lenvima (lenvatinib — Eisai oncology alliance revenue) — International sales ($M)($M)1 | 90 | 80 | 80 | 81 | 83 | 72 | 73 | 78 | 73 | 82 | 45 | 100 | |
Lenvima (lenvatinib — Eisai oncology alliance revenue) — International reported growth YoY (%)(%) | 8.0% | 11.0% | 4.0% | 14.0% | -12.0% | 63.0% | -22.0% | -7.0% | 3.0% | -28.0% | 67.0% | ||
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide reported growth YoY (%)(%) | 7.0% | 7.0% | 3.0% | 6.0% | 1.0% | 13.0% | -3.0% | 3.0% | 10.0% | 5.0% | 29.0% | ||
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 6.0% | 6.0% | 2.0% | 5.0% | 14.0% | 4.0% | 10.0% | 5.0% | 30.0% | ||||
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M)($M)4 | 122 | 148 | 164 | 136 | 107 | 119 | 110 | 100 | 90 | 71 | 70 | 52 | |
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M)($M)1 | 98 | 128 | 133 | 111 | 88 | 101 | 88 | 82 | 75 | 58 | 60 | 43 | |
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. reported growth YoY (%)(%) | 11.0% | 51.0% | 35.0% | 18.0% | 72.0% | 47.0% | 93.0% | 110.0% | 93.0% | 68.0% | 34.0% | ||
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — International sales ($M)($M)1 | 25 | 20 | 31 | 25 | 19 | 18 | 22 | 18 | 15 | 12 | 10 | 10 | |
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — International reported growth YoY (%)(%) | 31.0% | 37.0% | 40.0% | 24.0% | 47.0% | 124.0% | 83.0% | 36.0% | 74.0% | 42.0% | |||
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide reported growth YoY (%)(%) | 15.0% | 48.0% | 36.0% | 19.0% | 68.0% | 58.0% | 91.0% | 92.0% | 66.0% | 69.0% | 35.0% | ||
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 15.0% | 48.0% | 36.0% | 19.0% | 58.0% | 92.0% | 66.0% | 69.0% | 35.0% | ||||
Koselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M)($M) | 0 | 132 | 27 | 11 | 5 | 95 | 56 | 39 | 37 | 38 | 23 | 26 | |
Total Vaccines Franchise — Worldwide sales ($M)($M) | 0 | 132 | 579 | 703 | 5 | 95 | 546 | 592 | 715 | 745 | 2,962 | 4,002 | |
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide sales ($M)($M)5 | 1,169 | 1,069 | 1,031 | 1,749 | 1,126 | 1,327 | 1,550 | 2,306 | 2,478 | 2,249 | 1,871 | 2,585 | |
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. sales ($M)($M)1 | 542 | 485 | 406 | 1,154 | 545 | 536 | 380 | 1,020 | 536 | 488 | 365 | 838 | |
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. reported growth YoY (%)(%) | -1.0% | 7.0% | 13.0% | 2.0% | 10.0% | 4.0% | 22.0% | 17.0% | |||||
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International sales ($M)($M)1 | 626 | 585 | 625 | 595 | 581 | 790 | 1,170 | 1,285 | 1,941 | 1,761 | 1,506 | 1,746 | |
Gardasil / Gardasil 9 (HPV recombinant vaccine) — International reported growth YoY (%)(%) | 8.0% | -47.0% | -54.0% | -70.0% | -55.0% | -22.0% | -26.0% | 13.0% | |||||
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide reported growth YoY (%)(%) | 4.0% | -34.0% | -24.0% | -55.0% | -41.0% | -17.0% | -11.0% | 1.0% | 14.0% | ||||
Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 3.0% | -35.0% | -25.0% | -55.0% | -18.0% | 4.0% | 17.0% | ||||||
Gardasil / Gardasil 9 — China sales ($M)($M) | 0 | 0 | 0 | 193 | 446 | 517 | 1,312 | 1,253 | |||||
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M)($M)7 | 592 | 538 | 619 | 684 | 609 | 539 | 594 | 703 | 617 | 570 | 545 | 713 | |
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. sales ($M)($M)1 | 438 | 409 | 427 | 554 | 481 | 423 | 419 | 572 | 490 | 438 | 402 | 567 | |
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. reported growth YoY (%)(%) | -9.0% | 2.0% | -3.0% | -2.0% | -3.0% | 4.0% | 1.0% | 4.0% | |||||
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International sales ($M)($M)1 | 154 | 129 | 192 | 130 | 128 | 116 | 175 | 131 | 127 | 133 | 143 | 146 | |
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International reported growth YoY (%)(%) | 20.0% | 9.0% | -1.0% | 1.0% | -12.0% | 23.0% | -10.0% | 24.0% | |||||
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%)(%) | -3.0% | 4.0% | -3.0% | -1.0% | -5.0% | 9.0% | -1.0% | 6.0% | 8.0% | ||||
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -3.0% | 3.0% | -3.0% | -2.0% | 9.0% | 7.0% | 8.0% | ||||||
Varivax (varicella live virus vaccine) — Worldwide sales ($M)($M)2 | 260 | 235 | 264 | 288 | 240 | 249 | 274 | 301 | 266 | 262 | 252 | 325 | |
Varivax — Worldwide reported growth YoY (%)(%) | 8.0% | -6.0% | -4.0% | -10.0% | -5.0% | -7.0% | 4.0% | 11.0% | 16.0% | ||||
Varivax — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 8.0% | -7.0% | -5.0% | -10.0% | -4.0% | -7.0% | 5.0% | 11.0% | 15.0% | ||||
ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M)($M)2 | 235 | 198 | 262 | 273 | 273 | 121 | 203 | 274 | 239 | 204 | 192 | 267 | |
ProQuad — Worldwide reported growth YoY (%)(%) | -14.0% | 64.0% | 15.0% | -41.0% | 3.0% | 7.0% | 8.0% | 1.0% | |||||
ProQuad — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -15.0% | 60.0% | -1.0% | 14.0% | -40.0% | 3.0% | 8.0% | 7.0% | 1.0% | ||||
M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M)($M)2 | 96 | 105 | 93 | 123 | 95 | 168 | 118 | 129 | 113 | 104 | 101 | 122 | |
M-M-R II — Worldwide reported growth YoY (%)(%) | 1.0% | -38.0% | -5.0% | -15.0% | 62.0% | 5.0% | 8.0% | 2.0% | -2.0% | ||||
M-M-R II — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 1.0% | -39.0% | -6.0% | -16.0% | 63.0% | 6.0% | 9.0% | 2.0% | -4.0% | ||||
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide sales ($M)($M)4 | 148 | 202 | 140 | 226 | 229 | 230 | 161 | 239 | 189 | 219 | 176 | 214 | |
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. sales ($M)($M)1 | 69 | 123 | 50 | 134 | 136 | 139 | 64 | 137 | 99 | 161 | 138 | 182 | |
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%)(%) | -50.0% | -22.0% | -1.0% | 38.0% | -14.0% | -53.0% | -25.0% | -33.0% | 72.0% | 5.0% | |||
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — International sales ($M)($M) | 80 | 78 | 90 | 91 | 93 | 92 | 96 | 103 | 90 | 58 | 38 | 33 | |
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide reported growth YoY (%)(%) | -35.0% | -13.0% | -6.0% | 21.0% | 5.0% | -9.0% | 12.0% | 13.0% | 106.0% | 28.0% | |||
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -36.0% | -16.0% | -7.0% | 20.0% | -9.0% | 16.0% | 106.0% | 26.0% | |||||
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M)($M)2 | 184 | 142 | 279 | 244 | 129 | 107 | 50 | 97 | 50 | 47 | |||
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — U.S. sales ($M)($M) | 138 | 118 | 258 | 238 | 129 | 106 | 49 | 47 | 0 | 0 | |||
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — International sales ($M)($M) | 45 | 23 | 21 | 7 | 0 | 1 | 0 | 0 | 0 | 0 | |||
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide sales ($M)($M)4 | 134 | 206 | 119 | 204 | 121 | 228 | 139 | 193 | 163 | 216 | 185 | 156 | |
RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. sales ($M)($M)1 | 84 | 165 | 60 | 141 | 60 | 164 | 84 | 131 | 107 | 149 | 112 | 108 | |
RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. reported growth YoY (%)(%) | 39.0% | -28.0% | 8.0% | -44.0% | 10.0% | -25.0% | 21.0% | 15.0% | -17.0% | 37.0% | -30.0% | ||
RotaTeq (rotavirus live oral pentavalent vaccine) — International sales ($M)($M)1 | 50 | 42 | 59 | 63 | 61 | 64 | 55 | 62 | 56 | 67 | 73 | 48 | |
RotaTeq (rotavirus live oral pentavalent vaccine) — International reported growth YoY (%)(%) | -18.0% | 8.0% | 2.0% | 9.0% | -4.0% | -25.0% | 28.0% | 50.0% | -43.0% | 28.0% | -53.0% | ||
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide reported growth YoY (%)(%) | 10.0% | -14.0% | 6.0% | -26.0% | 5.0% | -25.0% | 24.0% | 25.0% | -27.0% | 34.0% | -39.0% | ||
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 9.0% | -15.0% | 5.0% | -26.0% | -25.0% | 26.0% | -27.0% | 33.0% | -39.0% | ||||
Vaqta (hepatitis A vaccine, legacy) — Worldwide sales ($M)($M)2 | 29 | 69 | |||||||||||
Vaqta (hepatitis A vaccine, legacy) — U.S. sales ($M)($M) | 28 | 32 | |||||||||||
Vaqta (hepatitis A vaccine, legacy) — International sales ($M)($M) | 1 | 37 | |||||||||||
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M)($M)2 | 588 | 525 | 467 | 360 | 336 | 280 | 200 | 200 | 149 | 70 | 0 | 0 | |
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — U.S. sales ($M)($M) | 522 | 477 | 432 | 335 | 323 | 268 | 192 | 147 | 70 | 0 | 0 | 0 | |
Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M)($M) | 66 | 48 | 35 | 25 | 12 | 12 | 9 | 3 | 0 | 0 | 0 | 0 | |
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — Worldwide sales ($M)($M)1 | 204 | 131 | 0 | 0 | |||||||||
Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — International sales ($M)($M) | 0 | 0 | 0 | 0 | |||||||||
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide sales ($M)($M)5 | 126 | 109 | 129 | 112 | 123 | 106 | 109 | 102 | 106 | 98 | 108 | 92 | |
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. sales ($M)($M)1 | 112 | 109 | 112 | 103 | 108 | 97 | 105 | 96 | 98 | 90 | 102 | 96 | |
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. reported growth YoY (%)(%) | 4.0% | 7.0% | 8.0% | 10.0% | 8.0% | 3.0% | -1.0% | 41.0% | 8.0% | 20.0% | 13.0% | ||
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International sales ($M)($M)1 | 14 | 0 | 17 | 8 | 15 | 9 | 5 | 7 | 8 | 8 | 6 | -4 | |
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International reported growth YoY (%)(%) | -1.0% | 25.0% | 89.0% | 12.0% | -27.0% | -51.0% | |||||||
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide reported growth YoY (%)(%) | 3.0% | 18.0% | 9.0% | 16.0% | 8.0% | 1.0% | 11.0% | 56.0% | -1.0% | 31.0% | 5.0% | ||
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 3.0% | 18.0% | 9.0% | 16.0% | 1.0% | 56.0% | -1.0% | 31.0% | 5.0% | ||||
Adempas (riociguat — direct Merck territory sales) — Worldwide sales ($M)($M)4 | 78 | 78 | 83 | 82 | 80 | 68 | 73 | 72 | 72 | 70 | 66 | 65 | |
Adempas (riociguat — direct Merck territory sales) — U.S. sales ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Adempas (riociguat — direct Merck territory sales) — International sales ($M)($M) | 78 | 78 | 83 | 82 | 80 | 68 | 73 | 72 | 72 | 70 | 66 | 65 | |
Adempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%)(%) | -2.0% | 14.0% | 14.0% | 10.0% | 11.0% | 11.0% | 18.0% | 15.0% | 15.0% | ||||
Adempas (riociguat — direct Merck territory sales) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -4.0% | 9.0% | 7.0% | 6.0% | 9.0% | 15.0% | 18.0% | 11.0% | 11.0% | ||||
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide sales ($M)($M)4 | 497 | 472 | 499 | 439 | 461 | 441 | 449 | 420 | 455 | 440 | 429 | 424 | |
Bridion (sugammadex — neuromuscular blockade reversal) — U.S. sales ($M)($M)1 | 460 | 427 | 451 | 392 | 411 | 378 | 382 | 339 | 351 | 329 | 315 | 265 | |
Bridion (sugammadex — neuromuscular blockade reversal) — U.S. reported growth YoY (%)(%) | 12.0% | 18.0% | 15.0% | 17.0% | 15.0% | 21.0% | 28.0% | 17.0% | 19.0% | 22.0% | 14.0% | ||
Bridion (sugammadex — neuromuscular blockade reversal) — International sales ($M)($M)1 | 37 | 45 | 49 | 47 | 50 | 63 | 67 | 81 | 104 | 111 | 113 | 159 | |
Bridion (sugammadex — neuromuscular blockade reversal) — International reported growth YoY (%)(%) | -25.0% | -28.0% | -42.0% | -52.0% | -43.0% | -41.0% | -49.0% | -49.0% | -47.0% | -38.0% | -17.0% | ||
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide reported growth YoY (%)(%) | 8.0% | 11.0% | 5.0% | 1.0% | 5.0% | -1.0% | -9.0% | -10.0% | -3.0% | ||||
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 8.0% | 11.0% | 4.0% | 1.0% | 5.0% | -8.0% | -8.0% | -3.0% | |||||
Prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M)($M)4 | 295 | 272 | 275 | 266 | 228 | 208 | 215 | 208 | 188 | 174 | 175 | 157 | |
Prevymis (letermovir — CMV prophylaxis) — U.S. sales ($M)($M)1 | 147 | 135 | 130 | 128 | 115 | 102 | 106 | 101 | 90 | 74 | 78 | 70 | |
Prevymis (letermovir — CMV prophylaxis) — U.S. reported growth YoY (%)(%) | 28.0% | 23.0% | 27.0% | 27.0% | 37.0% | 36.0% | 43.0% | 47.0% | 37.0% | 49.0% | 43.0% | ||
Prevymis (letermovir — CMV prophylaxis) — International sales ($M)($M)1 | 148 | 138 | 146 | 138 | 113 | 106 | 109 | 107 | 98 | 100 | 98 | 87 | |
Prevymis (letermovir — CMV prophylaxis) — International reported growth YoY (%)(%) | 31.0% | 33.0% | 29.0% | 16.0% | 6.0% | 12.0% | 24.0% | 19.0% | 33.0% | 50.0% | 35.0% | ||
Prevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%)(%) | 29.0% | 28.0% | 28.0% | 21.0% | 19.0% | 23.0% | 32.0% | 31.0% | 35.0% | 49.0% | 38.0% | ||
Prevymis (letermovir — CMV prophylaxis) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 28.0% | 26.0% | 25.0% | 20.0% | 23.0% | 35.0% | 39.0% | 49.0% | 38.0% | ||||
Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M)($M)4 | 22 | 34 | 25 | 43 | 96 | 83 | 79 | 96 | 92 | 73 | 87 | 74 | |
Dificid (fidaxomicin — C. difficile infection) — U.S. sales ($M)($M)1 | 11 | 24 | 17 | 30 | 83 | 72 | 72 | 83 | 79 | 68 | 75 | 69 | |
Dificid (fidaxomicin — C. difficile infection) — U.S. reported growth YoY (%)(%) | -87.0% | -76.0% | -64.0% | 4.0% | 6.0% | -4.0% | 20.0% | 16.0% | 10.0% | 32.0% | -3.0% | ||
Dificid (fidaxomicin — C. difficile infection) — International sales ($M)($M)1 | 12 | 10 | 8 | 13 | 13 | 11 | 7 | 13 | 12 | 5 | 12 | 5 | |
Dificid (fidaxomicin — C. difficile infection) — International reported growth YoY (%)(%) | -11.0% | 13.0% | -2.0% | 8.0% | 117.0% | -42.0% | 190.0% | 56.0% | 49.0% | 17.0% | -20.0% | ||
Dificid (fidaxomicin — C. difficile infection) — Worldwide reported growth YoY (%)(%) | -77.0% | -68.0% | -55.0% | 5.0% | 13.0% | -9.0% | 31.0% | 20.0% | 12.0% | 30.0% | -4.0% | ||
Dificid (fidaxomicin — C. difficile infection) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -77.0% | -68.0% | -55.0% | 5.0% | -9.0% | 20.0% | 12.0% | 30.0% | -4.0% | ||||
Zerbaxa (ceftolozane and tazobactam) — Worldwide sales ($M)($M)4 | 77 | 82 | 87 | 81 | 74 | 70 | 70 | 64 | 62 | 56 | 61 | 53 | |
Zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M)($M)1 | 44 | 52 | 50 | 49 | 45 | 42 | 40 | 39 | 33 | 33 | 33 | 29 | |
Zerbaxa (ceftolozane and tazobactam) — U.S. reported growth YoY (%)(%) | -3.0% | 25.0% | 25.0% | 35.0% | 27.0% | 23.0% | 34.0% | 12.0% | 23.0% | 31.0% | 19.0% | ||
Zerbaxa (ceftolozane and tazobactam) — International sales ($M)($M)1 | 34 | 30 | 36 | 32 | 29 | 28 | 30 | 26 | 28 | 23 | 28 | 24 | |
Zerbaxa (ceftolozane and tazobactam) — International reported growth YoY (%)(%) | 14.0% | 23.0% | 25.0% | 5.0% | 20.0% | 4.0% | 6.0% | 17.0% | 1.0% | 18.0% | 27.0% | ||
Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%)(%) | 4.0% | 24.0% | 25.0% | 21.0% | 24.0% | 14.0% | 22.0% | 14.0% | 13.0% | 25.0% | 23.0% | ||
Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 2.0% | 23.0% | 24.0% | 21.0% | 16.0% | 18.0% | 15.0% | 23.0% | 22.0% | ||||
Primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M)($M)4 | 39 | 41 | |||||||||||
Primaxin (imipenem and cilastatin, legacy) — U.S. sales ($M)($M) | -1 | 0 | |||||||||||
Primaxin (imipenem and cilastatin, legacy) — International sales ($M)($M) | 38 | 41 | |||||||||||
Primaxin (imipenem and cilastatin, legacy) — Worldwide reported growth YoY (%)(%) | -28.0% | -35.0% | |||||||||||
Primaxin (imipenem and cilastatin, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -28.0% | -31.0% | |||||||||||
Noxafil (posaconazole, legacy) — Worldwide sales ($M)($M)4 | 36 | 41 | 45 | 56 | 46 | 51 | |||||||
Noxafil (posaconazole, legacy) — U.S. sales ($M)($M)1 | -2 | 1 | 0 | 8 | 4 | 4 | |||||||
Noxafil (posaconazole, legacy) — U.S. reported growth YoY (%)(%) | -149.0% | -85.0% | -43.0% | -72.0% | -71.0% | ||||||||
Noxafil (posaconazole, legacy) — International sales ($M)($M)1 | 37 | 40 | 44 | 48 | 43 | 47 | |||||||
Noxafil (posaconazole, legacy) — International reported growth YoY (%)(%) | -12.0% | -15.0% | 4.0% | -7.0% | -3.0% | ||||||||
Noxafil (posaconazole, legacy) — Worldwide reported growth YoY (%)(%) | -23.0% | -20.0% | -20.0% | -7.0% | -21.0% | -18.0% | |||||||
Noxafil (posaconazole, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -17.0% | -9.0% | 4.0% | -16.0% | -12.0% | ||||||||
Total Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M)2 | |||||||||||||
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide sales ($M)($M)4 | 258 | 367 | 302 | 382 | 372 | 549 | 232 | 278 | 405 | 419 | 547 | 581 | |
Januvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M)($M)1 | 149 | 252 | 180 | 258 | 216 | 344 | 41 | 67 | 177 | 183 | 309 | 328 | |
Januvia (sitagliptin — DPP-4 inhibitor) — U.S. reported growth YoY (%)(%) | -31.0% | 22.0% | 88.0% | -87.0% | -80.0% | -27.0% | -32.0% | 6.0% | -1.0% | ||||
Januvia (sitagliptin — DPP-4 inhibitor) — International sales ($M)($M)1 | 109 | 116 | 122 | 124 | 155 | 204 | 191 | 211 | 227 | 236 | 239 | 252 | |
Januvia (sitagliptin — DPP-4 inhibitor) — International reported growth YoY (%)(%) | -30.0% | -36.0% | -42.0% | -32.0% | -13.0% | -20.0% | -16.0% | -15.0% | -16.0% | -12.0% | -34.0% | ||
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%)(%) | -31.0% | 30.0% | 37.0% | -8.0% | 31.0% | -58.0% | -52.0% | -21.0% | -24.0% | -2.0% | -19.0% | ||
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -30.0% | 30.0% | 37.0% | -8.0% | -56.0% | -16.0% | -21.0% | -2.0% | -17.0% | ||||
Janumet (sitagliptin and metformin HCl) — Worldwide sales ($M)($M)4 | 171 | 207 | 199 | 243 | 251 | 247 | 255 | 204 | 224 | 251 | 240 | 255 | |
Janumet (sitagliptin and metformin HCl) — U.S. sales ($M)($M)1 | 28 | 68 | 57 | 78 | 68 | 65 | 91 | 15 | 17 | 39 | 41 | 43 | |
Janumet (sitagliptin and metformin HCl) — U.S. reported growth YoY (%)(%) | -59.0% | -37.0% | 68.0% | 122.0% | -67.0% | -80.0% | -32.0% | -58.0% | -52.0% | ||||
Janumet (sitagliptin and metformin HCl) — International sales ($M)($M)1 | 143 | 139 | 142 | 165 | 184 | 182 | 164 | 190 | 208 | 212 | 198 | 211 | |
Janumet (sitagliptin and metformin HCl) — International reported growth YoY (%)(%) | -22.0% | -14.0% | -13.0% | -12.0% | -14.0% | -17.0% | -10.0% | -24.0% | -22.0% | -22.0% | -35.0% | ||
Janumet (sitagliptin and metformin HCl) — Worldwide reported growth YoY (%)(%) | -32.0% | -22.0% | 19.0% | 12.0% | -2.0% | 7.0% | -20.0% | -37.0% | -24.0% | -32.0% | -39.0% | ||
Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -33.0% | -22.0% | 20.0% | 14.0% | 11.0% | -32.0% | -20.0% | -32.0% | -38.0% | ||||
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide sales ($M)($M)4 | 5 | 28 | 57 | 138 | 83 | 102 | 121 | 383 | 110 | 350 | 193 | 640 | |
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — U.S. sales ($M)($M) | 1 | 16 | 11 | 24 | 30 | 35 | 32 | 84 | 15 | 45 | 10 | 0 | |
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — International sales ($M)($M)1 | 3 | 12 | 45 | 114 | 52 | 67 | 88 | 299 | 95 | 305 | 183 | 640 | |
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — International reported growth YoY (%)(%) | -94.0% | -49.0% | -62.0% | -45.0% | -78.0% | -52.0% | -53.0% | -23.0% | |||||
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide reported growth YoY (%)(%) | -95.0% | -53.0% | -64.0% | -25.0% | -71.0% | -37.0% | -46.0% | -11.0% | -77.0% | 47.0% | |||
Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -95.0% | -53.0% | -65.0% | -27.0% | -37.0% | -42.0% | -5.0% | -76.0% | 51.0% | ||||
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide sales ($M)($M)4 | 60 | 59 | 67 | 82 | 86 | 90 | 92 | 102 | 89 | 111 | 105 | 119 | |
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M)($M)1 | 36 | 35 | 37 | 44 | 48 | 51 | 38 | 54 | 43 | 50 | 50 | 58 | |
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. reported growth YoY (%)(%) | -26.0% | -3.0% | -18.0% | 13.0% | 2.0% | -23.0% | -6.0% | -24.0% | -3.0% | ||||
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International sales ($M)($M)1 | 24 | 24 | 30 | 37 | 38 | 39 | 53 | 48 | 46 | 61 | 56 | 61 | |
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — International reported growth YoY (%)(%) | -36.0% | -44.0% | -23.0% | -18.0% | -35.0% | -4.0% | -21.0% | -42.0% | -14.0% | ||||
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide reported growth YoY (%)(%) | -30.0% | -27.0% | -20.0% | -3.0% | -19.0% | -13.0% | -14.0% | -35.0% | -10.0% | ||||
Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -31.0% | -28.0% | -21.0% | -4.0% | -7.0% | -31.0% | -7.0% | ||||||
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M)($M)4 | 101 | 75 | 79 | 77 | 83 | 67 | 69 | 65 | 60 | 56 | 54 | 54 | |
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. sales ($M)($M)1 | 13 | 10 | 14 | 13 | 14 | 15 | 14 | 15 | 14 | 12 | 12 | 13 | |
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. reported growth YoY (%)(%) | -7.0% | -1.0% | -13.0% | -5.0% | 28.0% | 19.0% | 15.0% | 13.0% | 9.0% | ||||
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International sales ($M)($M)1 | 88 | 65 | 65 | 64 | 70 | 52 | 55 | 50 | 45 | 44 | 42 | 40 | |
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International reported growth YoY (%)(%) | 27.0% | 19.0% | 29.0% | 55.0% | 17.0% | 30.0% | 23.0% | 21.0% | 34.0% | ||||
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide reported growth YoY (%)(%) | 21.0% | 15.0% | 19.0% | 40.0% | 19.0% | 28.0% | 21.0% | 19.0% | 28.0% | ||||
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 17.0% | 9.0% | 13.0% | 35.0% | 29.0% | 23.0% | 30.0% | ||||||
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M)($M)4 | 42 | 43 | 41 | 45 | 40 | 42 | 39 | 42 | 33 | 37 | |||
Pifeltro (doravirine — HIV-1 NNRTI) — U.S. sales ($M)($M)1 | 26 | 29 | 25 | 32 | 26 | 31 | 27 | 29 | 23 | 27 | |||
Pifeltro (doravirine — HIV-1 NNRTI) — U.S. reported growth YoY (%)(%) | -3.0% | -7.0% | -4.0% | 8.0% | 16.0% | 12.0% | -1.0% | 22.0% | |||||
Pifeltro (doravirine — HIV-1 NNRTI) — International sales ($M)($M)1 | 17 | 14 | 16 | 13 | 13 | 12 | 12 | 13 | 10 | 10 | |||
Pifeltro (doravirine — HIV-1 NNRTI) — International reported growth YoY (%)(%) | 23.0% | 21.0% | 26.0% | 2.0% | 29.0% | 20.0% | 15.0% | 25.0% | |||||
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide reported growth YoY (%)(%) | 6.0% | 1.0% | 5.0% | 7.0% | 20.0% | 14.0% | 3.0% | 23.0% | |||||
Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 4.0% | -1.0% | 4.0% | 20.0% | 4.0% | 23.0% | |||||||
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M)($M)2 | 0 | 0 | 0 | 0 | 543 | 189 | 172 | 184 | 710 | 171 | |||
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)(%) | -4.0% | 2.0% | 3.0% | 3.0% | |||||||||
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -24.0% | -2.0% | 1.0% | -2.0% | -2.0% | ||||||||
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M)($M)1 | 0 | 0 | 0 | 0 | 114 | 41 | 35 | 39 | 187 | 43 | |||
Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)(%) | -27.0% | -24.0% | -1.0% | -8.0% | |||||||||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M)($M)4 | 49 | 47 | 40 | 50 | 45 | 78 | 53 | 46 | 54 | 58 | |||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M)($M)1 | 22 | 28 | 18 | 13 | 19 | 20 | 19 | 15 | 21 | 23 | |||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. reported growth YoY (%)(%) | 18.0% | 40.0% | -1.0% | -10.0% | -12.0% | -12.0% | -12.0% | -9.0% | 10.0% | 12.0% | |||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International sales ($M)($M)1 | 27 | 19 | 21 | 37 | 26 | 58 | 34 | 32 | 33 | 35 | |||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International reported growth YoY (%)(%) | 1.0% | -67.0% | -37.0% | 16.0% | -20.0% | 66.0% | -18.0% | -21.0% | -17.0% | -15.0% | |||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide reported growth YoY (%)(%) | 8.0% | -40.0% | -24.0% | 8.0% | -17.0% | 35.0% | -16.0% | -17.0% | -8.0% | -6.0% | |||
Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 9.0% | -40.0% | -26.0% | -17.0% | -8.0% | -11.0% | -6.0% | -4.0% | |||||
Other Pharmaceutical Products — Worldwide sales ($M)($M)5 | 641 | 774 | 770 | 1,004 | 703 | 865 | 699 | 638 | 618 | 632 | 576 | 568 | |
Other Pharmaceutical Products — U.S. sales ($M)($M)1 | 150 | 166 | 126 | 239 | 184 | 184 | 121 | 167 | 190 | 165 | 137 | 189 | |
Other Pharmaceutical Products — U.S. reported growth YoY (%)(%) | -18.0% | 4.0% | 43.0% | -28.0% | 12.0% | 26.0% | 13.0% | 20.0% | -8.0% | -20.0% | 2.0% | ||
Other Pharmaceutical Products — International sales ($M)($M)1 | 489 | 608 | 531 | 716 | 520 | 545 | 581 | 466 | 430 | 467 | 438 | 381 | |
Other Pharmaceutical Products — International reported growth YoY (%)(%) | -6.0% | -9.0% | 54.0% | 5.0% | 17.0% | 24.0% | 12.0% | -4.0% | -8.0% | 11.0% | -14.0% | ||
Other Pharmaceutical Products — Worldwide reported growth YoY (%)(%) | -9.0% | -6.0% | 50.0% | -6.0% | 16.0% | 25.0% | 13.0% | 2.0% | -8.0% | 2.0% | -9.0% | ||
Other Pharmaceutical Products — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | -9.0% | -5.0% | 49.0% | -7.0% | 25.0% | 6.0% | -6.0% | 2.0% | -7.0% | ||||
Upfront & milestone payments received for out-licensed products — Worldwide ($M)($M) | 0 | 132 | 27 | 11 | 5 | 95 | 15 | 15 | 15 | 61 | |||
Animal Health Segment — Worldwide sales ($M)($M)6 | 1,775 | 1,791 | 1,505 | 1,615 | 1,646 | 1,588 | 1,397 | 1,487 | 1,482 | 1,511 | 1,278 | 1,400 | |
Animal Health Segment — U.S. sales ($M)($M)1 | 535 | 448 | 504 | 499 | 502 | 444 | 487 | 455 | 474 | 387 | 462 | ||
Animal Health Segment — U.S. reported growth YoY (%)(%) | 7.0% | 1.0% | 3.0% | 9.0% | 6.0% | 15.0% | 6.0% | -4.0% | -2.0% | -2.0% | -3.0% | ||
Animal Health Segment — International sales ($M)($M)1 | 1,240 | 1,056 | 1,112 | 1,147 | 1,086 | 953 | 999 | 1,027 | 1,037 | 891 | 938 | ||
Animal Health Segment — International reported growth YoY (%)(%) | 8.0% | 11.0% | 11.0% | 12.0% | 5.0% | 7.0% | 6.0% | 5.0% | 3.0% | 7.0% | 5.0% | ||
Animal Health Segment — Worldwide reported growth YoY (%)(%) | 8.0% | 8.0% | 9.0% | 11.0% | 5.0% | 9.0% | 6.0% | 2.0% | 1.0% | 4.0% | 2.0% | ||
Animal Health Segment — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 5.0% | 6.0% | 7.0% | 11.0% | 13.0% | 6.0% | 4.0% | 4.0% | 2.0% | ||||
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide sales ($M)($M)4 | 1,041 | 1,064 | 987 | 1,023 | 961 | 924 | 889 | 886 | 837 | 850 | 808 | 874 | |
Animal Health — Livestock (cattle, poultry, swine & aqua) — U.S. sales ($M)($M)1 | 202 | 211 | 209 | 213 | 190 | 194 | 203 | 194 | 168 | 166 | 158 | 205 | |
Animal Health — Livestock (cattle, poultry, swine & aqua) — U.S. reported growth YoY (%)(%) | 6.0% | 3.0% | 10.0% | 13.0% | 17.0% | 28.0% | -5.0% | 2.0% | -5.0% | -16.0% | 10.0% | ||
Animal Health — Livestock (cattle, poultry, swine & aqua) — International sales ($M)($M)1 | 838 | 853 | 777 | 811 | 771 | 730 | 686 | 692 | 669 | 683 | 649 | 669 | |
Animal Health — Livestock (cattle, poultry, swine & aqua) — International reported growth YoY (%)(%) | 9.0% | 13.0% | 17.0% | 15.0% | 7.0% | 6.0% | 3.0% | 4.0% | 1.0% | 4.0% | 4.0% | ||
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide reported growth YoY (%)(%) | 8.0% | 11.0% | 16.0% | 15.0% | 9.0% | 10.0% | 1.0% | 4.0% | -1.0% | 5.0% | |||
Animal Health — Livestock (cattle, poultry, swine & aqua) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 6.0% | 9.0% | 14.0% | 16.0% | 14.0% | 11.0% | 4.0% | 7.0% | |||||
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide sales ($M)($M)5 | 734 | 727 | 518 | 592 | 685 | 664 | 508 | 601 | 645 | 661 | 470 | 526 | |
Animal Health — Companion Animal (vaccines & parasiticides) — U.S. sales ($M)($M)1 | 333 | 308 | 239 | 291 | 309 | 308 | 241 | 293 | 287 | 308 | 229 | 257 | |
Animal Health — Companion Animal (vaccines & parasiticides) — U.S. reported growth YoY (%)(%) | 8.0% | -1.0% | -1.0% | 8.0% | 5.0% | 14.0% | -7.0% | 10.0% | -11.0% | ||||
Animal Health — Companion Animal (vaccines & parasiticides) — International sales ($M)($M)1 | 402 | 419 | 279 | 301 | 376 | 356 | 267 | 307 | 358 | 354 | 242 | 269 | |
Animal Health — Companion Animal (vaccines & parasiticides) — International reported growth YoY (%)(%) | 7.0% | 4.0% | -2.0% | 5.0% | 1.0% | 11.0% | 14.0% | 6.0% | 6.0% | 16.0% | 6.0% | ||
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide reported growth YoY (%)(%) | 7.0% | 2.0% | -2.0% | 6.0% | 8.0% | 14.0% | -1.0% | 3.0% | 13.0% | -3.0% | |||
Animal Health — Companion Animal (vaccines & parasiticides) — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 5.0% | 0.0% | -3.0% | 6.0% | 10.0% | 1.0% | 4.0% | 12.0% | -4.0% | ||||
Bravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed)($M)1 | 359 | 379 | 262 | 335 | 266 | 235 | |||||||
Bravecto — Worldwide reported growth YoY (%)(%) | 7.0% | 16.0% | -1.0% | 1.0% | -3.0% | ||||||||
Pharmaceutical Segment — Worldwide sales ($M)($M)11 | 14,760 | 14,349 | 14,843 | 15,611 | 14,050 | 13,638 | 14,042 | 14,943 | 14,408 | 14,006 | 13,141 | 14,263 | |
Pharmaceutical Sales — United States ($M)($M)2 | 8,827 | 8,512 | 8,662 | 9,493 | 8,328 | 7,927 | 7,728 | 8,227 | 7,399 | 6,936 | 6,698 | 7,153 | |
Pharmaceutical Sales — United States share of Pharmaceutical revenue (%)(%) | 59.8% | 59.3% | 58.4% | 60.8% | 59.3% | 58.1% | 55.0% | 55.1% | 51.4% | 49.5% | 51.0% | 50.1% | |
Pharmaceutical Segment — U.S. reported growth YoY (%)(%) | 6.0% | 12.0% | 15.0% | 13.0% | 14.0% | 15.0% | 15.0% | 13.0% | 13.0% | 14.0% | 8.0% | ||
Pharmaceutical Sales — Europe ($M)($M)1 | 2,801 | 2,725 | 2,839 | 2,675 | 2,551 | 2,384 | 2,498 | 2,620 | 2,572 | 2,555 | 2,491 | 2,497 | |
Pharmaceutical Sales — Europe share of Pharmaceutical revenue (%)(%) | 19.0% | 19.0% | 19.1% | 17.1% | 18.2% | 17.5% | 17.8% | 17.5% | 17.9% | 18.2% | 19.0% | 17.5% | |
Pharmaceutical Sales — China ($M)($M)1 | 368 | 353 | 364 | 377 | 407 | 668 | 864 | 996 | 1,790 | 1,744 | 1,456 | 1,674 | |
Pharmaceutical Sales — China share of Pharmaceutical revenue (%)(%) | 2.5% | 2.5% | 2.5% | 2.4% | 2.9% | 4.9% | 6.2% | 6.7% | 12.4% | 12.5% | 11.1% | 11.7% | |
Pharmaceutical Sales — Japan ($M)($M)1 | 558 | 535 | 684 | 693 | 604 | 651 | 813 | 919 | 664 | 802 | 629 | 1,062 | |
Pharmaceutical Sales — Japan share of Pharmaceutical revenue (%)(%) | 3.8% | 3.7% | 4.6% | 4.4% | 4.3% | 4.8% | 5.8% | 6.2% | 4.6% | 5.7% | 4.8% | 7.4% | |
Pharmaceutical Sales — Asia Pacific (other than China and Japan) ($M)($M)1 | 636 | 569 | 586 | 593 | 609 | 535 | 612 | 669 | 595 | 580 | 616 | 636 | |
Pharmaceutical Sales — Asia Pacific (other than China and Japan) share of Pharmaceutical revenue (%)(%) | 4.3% | 4.0% | 4.0% | 3.8% | 4.3% | 3.9% | 4.4% | 4.5% | 4.1% | 4.1% | 4.7% | 4.5% | |
Pharmaceutical Sales — Latin America ($M)($M)1 | 636 | 624 | 644 | 691 | 654 | 589 | 680 | 730 | 661 | 601 | 596 | 696 | |
Pharmaceutical Sales — Latin America share of Pharmaceutical revenue (%)(%) | 4.3% | 4.3% | 4.3% | 4.4% | 4.7% | 4.3% | 4.8% | 4.9% | 4.6% | 4.3% | 4.5% | 4.9% | |
Pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M)($M)1 | 408 | 413 | 348 | 365 | 451 | 435 | 348 | 400 | 353 | 395 | 299 | 301 | |
Pharmaceutical Sales — Eastern Europe / Middle East / Africa share of Pharmaceutical revenue (%)(%) | 2.8% | 2.9% | 2.3% | 2.3% | 3.2% | 3.2% | 2.5% | 2.7% | 2.4% | 2.8% | 2.3% | 2.1% | |
Pharmaceutical Sales — Canada ($M)($M)1 | 154 | 137 | 153 | 134 | 135 | 125 | 144 | 133 | 143 | 138 | 138 | 133 | |
Pharmaceutical Sales — Canada share of Pharmaceutical revenue (%)(%) | 1.0% | 1.0% | 1.0% | 0.9% | 1.0% | 0.9% | 1.0% | 0.9% | 1.0% | 1.0% | 1.1% | 0.9% | |
Pharmaceutical Sales — Other Countries ($M)($M)1 | 372 | 481 | 563 | 590 | 311 | 324 | 355 | 249 | 231 | 255 | 218 | 111 | |
Pharmaceutical Sales — Other Countries share of Pharmaceutical revenue (%)(%) | 2.5% | 3.3% | 3.8% | 3.9% | 2.1% | 2.4% | 2.5% | 1.5% | 1.6% | 1.9% | 1.5% | 0.9% | |
Pharmaceutical Segment — Worldwide reported growth YoY (%)(%) | 5.0% | 6.0% | 4.0% | -2.0% | -3.0% | 7.0% | 5.0% | 7.0% | 10.0% | 8.0% | 10.0% | ||
Pharmaceutical Segment — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 4.0% | 4.0% | 3.0% | -3.0% | 8.0% | 11.0% | 13.0% | 8.0% | 11.0% | ||||
Total Company Sales — Worldwide ($M)($M)5 | 16,607 | 16,286 | 16,400 | 17,276 | 15,806 | 15,529 | 15,624 | 16,657 | 16,112 | 15,775 | 14,630 | 15,962 | |
Total Company Sales — United States ($M)($M)1 | 9,367 | 9,164 | 9,139 | 10,012 | 8,836 | 8,522 | 8,188 | 8,736 | 7,876 | 7,478 | 7,088 | 7,715 | |
Total Company Sales — U.S. reported growth YoY (%)(%) | 6.0% | 12.0% | 15.0% | 12.0% | 14.0% | 16.0% | 13.0% | 12.0% | 12.0% | 13.0% | 5.0% | ||
Total Company Sales — International ($M)($M)1 | 7,240 | 7,122 | 7,261 | 7,264 | 6,969 | 7,007 | 7,436 | 7,922 | 8,236 | 8,297 | 7,542 | 8,247 | |
Total Company Sales — International reported growth YoY (%)(%) | 4.0% | -2.0% | -8.0% | -15.0% | -16.0% | -1.0% | -4.0% | 3.0% | 6.0% | 8.0% | |||
Other Revenues (alliance, royalty & third-party supply) — Worldwide ($M)($M)2 | 72 | 146 | 52 | 50 | 110 | 303 | 185 | 227 | 222 | 258 | 211 | 299 | |
Other Revenues — U.S. ($M)($M) | 5 | 29 | 15 | 9 | 93 | 16 | 22 | 22 | 68 | 3 | 100 | ||
Other Revenues — International ($M)($M) | 67 | 24 | 34 | 100 | 210 | 169 | 206 | 200 | 190 | 208 | 199 | ||
Total Company Sales — Worldwide reported growth YoY (%)(%) | 5.0% | 5.0% | 4.0% | -2.0% | -2.0% | 7.0% | 4.0% | 7.0% | 9.0% | 6.0% | 7.0% | ||
Total Company Sales — Worldwide constant-currency (ex-exchange) growth YoY (%)(%) | 4.0% | 4.0% | 3.0% | -2.0% | 9.0% | 11.0% | 12.0% | 7.0% | 9.0% | ||||
U.S. Aggregate Customer Discounts (Chargebacks & Rebates) Provision ($M)($M) | 2,500 | 2,500 | 2,800 | 2,600 | 2,500 | 2,100 | 3,200 | 3,600 | 3,300 | 3,200 | 3,100 | 3,100 | |
Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M)($M)6 | 84 | 84 | 85 | 84 | 86 | 83 | 133 | 82 | 82 | 82 | 81 | 82 | |
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current receivables from partner ($M)($M) | 375 | 401 | 451 | 436 | 411 | 358 | 424 | 375 | 349 | 334 | 341 | ||
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent receivables from partner ($M)($M) | 125 | 125 | 125 | 0 | |||||||||
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current payables / liabilities to partner ($M)($M) | 6 | 12 | 6 | 4 | 12 | 15 | 713 | 615 | 615 | 617 | 256 | 257 | |
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M) | 84 | 84 | 85 | 84 | 86 | 83 | 133 | 82 | 82 | 82 | 81 | 82 | |
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M)($M) | 9 | 5 | 5 | 3 | 16 | 12 | 20 | 19 | 18 | 20 | 14 | 23 | |
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M)($M) | 25 | 24 | 30 | 31 | 40 | 32 | 44 | 39 | 43 | 39 | 49 | 44 | |
Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M)($M)4 | 13 | 13 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 61 | 137 | |
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current receivables from partner ($M)($M) | 281 | 252 | 271 | 258 | 265 | 263 | 257 | 252 | 245 | 255 | 226 | ||
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M) | 13 | 13 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 61 | 137 | |
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M)($M) | 0 | 2 | 1 | 2 | 3 | 5 | 3 | 4 | 6 | 8 | 5 | 5 | |
Eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M)($M) | 29 | 27 | 35 | 33 | 35 | 31 | 39 | 40 | 41 | 39 | 44 | 46 | |
Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M)($M)5 | 67 | 67 | 66 | 71 | 61 | 58 | 62 | 59 | 61 | 62 | 59 | 53 | |
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current receivables from partner ($M)($M) | 166 | 162 | 167 | 168 | 173 | 160 | 160 | 166 | 170 | 155 | 156 | ||
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Current payables / liabilities to partner ($M)($M) | 86 | 87 | 81 | 93 | 88 | 83 | 82 | 82 | 81 | 74 | 80 | 82 | |
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M) | 67 | 67 | 66 | 71 | 61 | 58 | 62 | 59 | 61 | 62 | 59 | 53 | |
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Net R&D cost-sharing expense ($M)($M) | 10 | 17 | 1 | 11 | 20 | 24 | 20 | 27 | 28 | 28 | 14 | 26 | |
Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Commercialization / SG&A expense sharing ($M)($M) | 11 | 12 | 17 | 22 | 29 | 29 | 23 | 29 | 26 | 33 | 31 | 33 | |
Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M)($M)4 | 181 | 160 | -1 | 67 | 193 | 128 | 0 | 0 | 65 | 69 | 5,500 | 0 | |
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M)($M) | 27 | 22 | 15 | 17 | 21 | 13 | 8 | 0 | |||||
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M)($M) | 100 | 85 | 113 | 869 | 850 | 803 | 817 | 811 | 801 | 817 | 800 | ||
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M)($M) | 181 | 160 | 145 | 110 | 193 | 128 | 124 | 94 | 65 | 69 | 5,500 | 0 | |
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M)($M) | 12 | 12 | 7 | 8 | 4 | 9 | 5 | 5 | 14 | 3 | 3 | 0 | |
Collaboration — Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) ($M)($M)4 | 94 | 90 | 103 | 96 | 90 | 86 | 103 | 93 | 93 | 69 | 65 | 66 | |
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current receivables from partner ($M)($M) | 15 | 4 | 0 | 235 | 232 | 228 | 198 | 172 | 135 | 110 | |||
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current payables / liabilities to partner ($M)($M) | 0 | 0 | 13 | 13 | 22 | 37 | 57 | 68 | 73 | 72 | 63 | ||
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Net R&D cost-sharing expense ($M)($M) | 94 | 90 | 103 | 96 | 90 | 86 | 103 | 93 | 93 | 69 | 65 | 66 | |
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Commercialization / SG&A expense sharing ($M)($M) | 9 | 8 | 8 | 7 | 6 | 6 | 5 | 5 | 4 | 2 | 2 | 2 | |
Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M)($M)2 | 14 | 54 | 57 | 81 | 44 | 53 | 63 | 204 | 96 | 191 | 90 | 348 | |
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Cost of sales profit-sharing & manufacturing ($M)($M) | 14 | 54 | 57 | 81 | 44 | 53 | 63 | 204 | 96 | 191 | 90 | 348 | |
Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) — Commercialization / SG&A expense sharing ($M)($M) | 9 | 11 | 15 | 11 | 14 | 13 | 14 | 11 | 16 | 16 | 25 | 21 | |
Research & Development Expense — Pharmaceutical Segment ($M)($M)3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Research & Development Expense — Animal Health Segment ($M)($M) | 120 | 112 | 125 | 118 | 110 | 95 | 109 | 95 | 91 | 90 | |||
Merck Research Laboratories (MRL) Direct Human Health R&D ($B) | 2.80 | ||||||||||||
Acquired In-Process R&D (IPR&D) & Asset Acquisition Charges ($M)($M) | 5,271 | 8,540 | 0 | 0 | 0 | 0 | 700 | 2,100 | 0 | 656 | 10,217 | 0 | |
Non-GAAP Diluted Earnings per Share ($)($)9 | -0.13 | -1.28 | 2.04 | 2.58 | 2.13 | 2.22 | 1.72 | 1.57 | 2.28 | 2.07 | 0.03 | 2.13 | |
Non-GAAP Net Income Attributable to Merck & Co., Inc. ($M)($M) | -1,005 | -3,156 | 5,088 | 6,448 | 5,366 | 5,611 | 4,372 | 3,985 | 5,809 | 5,279 | 66 | 5,427 | |
Non-GAAP Income Before Taxes ($M)($M)3 | 550 | -2,202 | 6,010 | 7,450 | 6,311 | 6,548 | 5,220 | 5,106 | 6,767 | 6,296 | -1,573 | 6,391 | |
Total Pre-Tax Non-GAAP Adjustments ($M)($M) | -1,233 | -1,332 | -2,590 | 344 | -1,312 | 107 | -1,050 | -1,016 | 49 | 116 | 61 | ||
Acquisition & Divestiture-Related Pre-Tax Charges ($M)($M) | 191 | 1,046 | 1,107 | 61 | 1,233 | ||||||||
Restructuring Pre-Tax Charges ($M)($M) | 1,233 | 180 | 1,277 | 1,312 | 61 | ||||||||
Non-GAAP Cost of Sales ($M)($M)1 | 3,144 | 2,944 | 3,324 | 3,124 | 2,816 | 2,763 | 3,006 | 3,249 | 3,073 | 2,961 | 3,340 | 3,679 | |
Cost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M)($M) | 1,251 | 1,251 | 2,227 | 731 | 741 | 656 | 822 | 831 | 672 | 579 | 571 | 585 | |
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M) | 2,887 | 2,668 | 2,848 | 2,599 | 2,633 | 2,529 | 2,819 | 2,657 | 2,684 | 2,457 | 2,751 | 2,462 | |
Non-GAAP Research and Development (R&D) Expense ($M)($M) | 9,736 | 12,558 | 3,992 | 3,997 | 3,992 | 3,614 | 4,574 | 5,838 | 3,480 | 3,974 | 8,838 | 3,297 | |
Non-GAAP Other (Income) Expense, Net ($M)($M) | 290 | 318 | 226 | 5 | 31 | 108 | 174 | 133 | |||||
Non-GAAP Income Tax Provision ($M)($M) | 882 | 957 | 923 | 1,000 | 944 | 931 | 846 | 1,117 | 952 | 1,012 | 959 | ||
Non-GAAP Effective Income Tax Rate (%)(%) | 160.3% | -43.5% | 15.4% | 13.4% | 15.0% | 14.2% | 16.2% | 21.9% | 14.1% | 16.1% | 114.2% | 15.0% | |
GAAP Effective Income Tax Rate (%)(%) | -95.9% | -20.1% | 13.4% | 14.2% | 11.4% | 13.9% | 10.2% | 22.7% | 9.1% | 15.9% | 40.1% | 15.5% | |
Other (Income) Expense Breakdown — Interest Income ($M)($M)5 | -35 | -69 | -96 | -69 | -109 | -146 | -127 | -69 | -73 | -70 | -73 | ||
Other (Income) Expense Breakdown — Interest Expense ($M)($M) | 525 | 412 | 327 | 305 | 313 | 328 | 330 | 310 | 303 | 310 | 317 | ||
Other (Income) Expense Breakdown — Foreign Exchange Losses ($M)($M) | 37 | 99 | 56 | 78 | 90 | 49 | 33 | 60 | 83 | 162 | 85 | ||
Other (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M)($M) | -242 | 196 | -373 | -100 | -90 | 156 | 31 | -56 | -143 | -99 | 33 | ||
Other (Income) Expense Breakdown — Net Periodic Defined Benefit Plan (Credit) Cost ($M)($M) | -127 | -163 | -152 | -152 | -148 | -157 | -157 | -159 | -160 | -134 | -138 | ||
Other (Income) Expense Breakdown — Other, Net ($M)($M) | -59 | -43 | -69 | -91 | -104 | -272 | -44 | -43 | -91 | -98 | |||
Restructuring Programs — Total Period Charges Across All Programs ($M)($M)3 | 334 | 466 | 1,277 | 390 | 779 | 105 | 187 | 279 | 176 | 246 | 401 | 199 | |
Restructuring Programs — Total Ending Accrual Reserve ($M)($M) | 557 | 564 | 651 | 687 | 736 | 712 | 567 | ||||||
2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M)($M)5 | 162 | 148 | 216 | 88 | 130 | 105 | 187 | 279 | 177 | 246 | |||
2024 Restructuring Program (Supply Network & Commercial Optimization) — Expected Total Program Cost ($M)($M) | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | ||
2024 Restructuring Program (Supply Network & Commercial Optimization) — Cumulative Charges Incurred Since Inception ($M)($M) | 1,900 | 1,800 | 1,600 | 1,400 | 1,300 | 1,200 | 1,100 | 892 | 613 | 436 | |||
2024 Restructuring Program (Supply Network & Commercial Optimization) — Ending Accrual Reserve Balance ($M)($M) | 408 | 448 | 506 | 499 | 548 | 564 | 712 | ||||||
2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in Cost of Sales ($M)($M) | 99 | 93 | 113 | 38 | 65 | 36 | 121 | 192 | 66 | 116 | |||
2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in Restructuring Line Item ($M)($M) | 63 | 55 | 103 | 50 | 64 | 69 | 51 | 56 | 80 | 123 | |||
2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M)($M)4 | 211 | 199 | |||||||||||
2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M)($M) | 597 | ||||||||||||
2019 Restructuring Program (legacy) — Recorded in Cost of Sales ($M)($M) | 55 | 33 | |||||||||||
2019 Restructuring Program (legacy) — Recorded in R&D ($M)($M) | 0 | 0 | |||||||||||
2019 Restructuring Program (legacy) — Recorded in Restructuring Line Item ($M)($M) | 127 | 126 | |||||||||||
Total Inventories — Current & Noncurrent Net ($M)($M)4 | 12,588 | 12,674 | 12,339 | 11,856 | 11,483 | 10,752 | 10,302 | 10,239 | 9,925 | 9,923 | 9,706 | 9,282 | |
Current Inventories, Net ($M)($M) | 6,207 | 6,479 | 6,658 | 6,444 | 6,601 | 6,196 | 6,109 | 6,244 | 6,469 | 6,510 | 6,358 | 6,131 | |
Noncurrent Inventories included in Other Assets — Long-Term ($M)($M) | 5,900 | 5,800 | 5,500 | 5,200 | 4,300 | 4,000 | 3,800 | 3,700 | 3,200 | 2,600 | 2,600 | 2,400 | |
Total Gross Inventories before LIFO Reserve ($M)($M)3 | 13,689 | 13,681 | 13,251 | 12,739 | 12,342 | 11,598 | 11,142 | 11,001 | 10,612 | 10,544 | 10,268 | 9,751 | |
Inventories — Finished Goods ($M)($M) | 2,186 | 2,211 | 2,275 | 2,249 | 2,142 | 2,129 | 2,022 | 1,939 | 1,889 | 1,902 | 1,954 | 1,840 | |
Inventories — Raw Materials and Work in Process ($M)($M) | 11,194 | 11,136 | 10,645 | 10,165 | 9,888 | 9,179 | 8,831 | 8,780 | 8,456 | 8,366 | 8,037 | ||
Inventories — Supplies ($M)($M) | 309 | 334 | 331 | 325 | 312 | 290 | 289 | 282 | 267 | 276 | 277 | 281 | |
Inventories — LIFO Reserve Reduction ($M)($M) | 1,101 | 1,007 | 912 | 883 | 859 | 846 | 840 | 762 | 687 | 621 | 562 | 469 | |
Finite-Lived Intangible Assets — Products & Developed Technology, Net ($M)1 | |||||||||||||
Product Intangible Asset Carrying Value — Adempas (riociguat) ($M)($M) | 203 | 239 | 280 | 312 | 348 | 353 | 372 | 431 | 445 | 533 | |||
U.S. Defined Benefit Pension Plans — Funded Status ($M)4 | |||||||||||||
U.S. Defined Benefit Pension Plans — Service Cost ($M)($M) | 98 | 98 | 99 | 100 | 90 | 89 | 100 | 100 | 86 | 86 | 87 | 88 | |
U.S. Defined Benefit Pension Plans — Interest Cost ($M)($M) | 145 | 145 | 144 | 143 | 141 | 141 | 134 | 134 | 134 | 134 | 130 | 130 | |
U.S. Defined Benefit Pension Plans — Expected Return on Plan Assets ($M)($M) | 207 | 207 | 210 | 210 | 210 | 210 | 205 | 206 | 207 | 207 | 182 | 182 | |
U.S. Defined Benefit Pension Plans — Net Periodic Benefit Cost (Credit) ($M)($M) | 65 | 66 | 51 | 58 | 34 | 33 | 42 | 41 | 23 | 26 | 41 | 37 | |
International Defined Benefit Pension Plans — Funded Status ($M)4 | |||||||||||||
International Defined Benefit Pension Plans — Service Cost ($M)($M) | 49 | 48 | 57 | 57 | 60 | 54 | 61 | 60 | 60 | 61 | 48 | 48 | |
International Defined Benefit Pension Plans — Interest Cost ($M)($M) | 79 | 81 | 78 | 78 | 75 | 71 | 74 | 74 | 73 | 74 | 74 | 76 | |
International Defined Benefit Pension Plans — Expected Return on Plan Assets ($M)($M) | 158 | 161 | 159 | 159 | 152 | 143 | 138 | 139 | 137 | 139 | 127 | 131 | |
International Defined Benefit Pension Plans — Net Periodic Benefit Cost (Credit) ($M)($M) | -35 | -22 | -36 | -41 | -19 | -19 | -5 | -7 | -6 | -6 | -15 | -14 | |
Other Postretirement Benefit (OPEB) Plans — Funded Status ($M)4 | |||||||||||||
Other Postretirement Benefit (OPEB) Plans — Service Cost ($M)($M) | 11 | 11 | 8 | 9 | 9 | 10 | 7 | 7 | 8 | 8 | 8 | 8 | |
Other Postretirement Benefit (OPEB) Plans — Interest Cost ($M)($M) | 16 | 16 | 15 | 15 | 16 | 16 | 14 | 14 | 14 | 14 | 16 | 16 | |
Other Postretirement Benefit (OPEB) Plans — Expected Return on Plan Assets ($M)($M) | 14 | 14 | 11 | 13 | 13 | 14 | 20 | 20 | 20 | 20 | 16 | 16 | |
Other Postretirement Benefit (OPEB) Plans — Net Periodic Benefit Cost (Credit) ($M)($M) | -4 | -3 | -13 | -11 | -8 | -8 | -19 | -24 | -21 | -21 | -15 | -15 | |
Organon & Co. — Total Revenues ($M)($M)20 | 1,558 | 1,460 | 1,507 | 1,602 | 1,594 | 1,513 | 1,592 | 1,582 | 1,607 | 1,622 | 1,598 | 1,519 | |
Organon & Co. — Revenues from Related Party (Merck & Co., Inc. Transition/Supply) ($M)($M) | 13,000,000 | 13,000,000 | 14,000,000 | 18,000,000 | 19,000,000 | 18,000,000 | 26,000,000 | 25,000,000 | 28,000,000 | 29,000,000 | 27,000,000 | 28,000,000 | |
Organon Revenue — United States ($M)($M) | 398,000,000 | 358,000,000 | 372,000,000 | 406,000,000 | 414,000,000 | 412,000,000 | 416,000,000 | 398,000,000 | 388,000,000 | 371,000,000 | 411,000,000 | 370,000,000 | |
Organon Revenue — Total International ($M)($M) | 1,160,000,000 | 1,102,000,000 | 1,135,000,000 | 1,196,000,000 | 1,180,000,000 | 1,101,000,000 | 1,176,000,000 | 1,184,000,000 | 1,219,000,000 | 1,251,000,000 | 1,187,000,000 | 1,149,000,000 | |
Organon Revenue — Europe and Canada ($M)($M) | 432,000,000 | 412,000,000 | 406,000,000 | 417,000,000 | 419,000,000 | 376,000,000 | 420,000,000 | 436,000,000 | 457,000,000 | 450,000,000 | 414,000,000 | 392,000,000 | |
Organon Revenue — Asia Pacific and Japan ($M)($M) | 232,000,000 | 226,000,000 | 248,000,000 | 251,000,000 | 250,000,000 | 251,000,000 | 244,000,000 | 260,000,000 | 260,000,000 | 287,000,000 | 260,000,000 | 284,000,000 | |
Organon Revenue — China ($M)($M) | 208,000,000 | 194,000,000 | 202,000,000 | 219,000,000 | 204,000,000 | 204,000,000 | 213,000,000 | 212,000,000 | 216,000,000 | 206,000,000 | 203,000,000 | 202,000,000 | |
Organon Revenue — Latin America, Middle East, Russia and Africa (LAMERA) ($M)($M) | 269,000,000 | 247,000,000 | 262,000,000 | 286,000,000 | 285,000,000 | 240,000,000 | 266,000,000 | 243,000,000 | 251,000,000 | 274,000,000 | 278,000,000 | 239,000,000 | |
Organon Revenue — Other ($M)($M) | 19,000,000 | 23,000,000 | 17,000,000 | 23,000,000 | 22,000,000 | 30,000,000 | 33,000,000 | 33,000,000 | 35,000,000 | 34,000,000 | 32,000,000 | 32,000,000 | |
Organon & Co. — Gross Profit ($M)($M) | 847 | 783 | 741 | 857 | 874 | 841 | 896 | 923 | 939 | 957 | 915 | 907 | |
Organon & Co. — Cost of Sales ($M)($M) | 711 | 677 | 766 | 745 | 720 | 672 | 696 | 659 | 668 | 665 | 683 | 612 | |
Organon & Co. — Selling, General and Administrative (SG&A) ($M)($M) | 434 | 424 | 433 | 415 | 453 | 420 | 470 | 422 | 437 | 431 | 469 | 538 | |
Organon & Co. — Restructuring Charges ($M)($M) | 0 | 31 | 7 | 0 | 2 | 86 | 8 | 0 | 0 | 23 | 58 | 0 | |
Organon & Co. — Net Income ($M)($M) | 108 | 146 | -205 | 160 | 145 | 87 | 109 | 359 | 195 | 201 | 546 | 58 | |
Organon & Co. — Diluted EPS ($)($) | 0.40 | 0.55 | 0.61 | 0.56 | 0.33 | 1.38 | 0.75 | 0.78 | 0.23 | ||||
Organon & Co. — Operating Cash Flow ($M)($M) | 107 | 225 | 141 | 264 | 220 | 75 | 390 | 141 | 332 | 76 | 397 | 261 | |
Organon & Co. — Capital Expenditures ($M)($M) | 42 | 37 | 45 | 46 | 39 | 32 | 55 | 42 | 32 | 46 | 79 | 55 | |
Organon & Co. — Cash and Cash Equivalents ($M)($M) | 1,132 | 1,116 | 574 | 672 | 599 | 547 | 675 | 763 | 704 | 575 | 693 | 414 | |
Organon & Co. — Inventories ($M)($M) | 1,351 | 1,373 | 1,406 | 1,488 | 1,454 | 1,362 | 1,321 | 1,383 | 1,287 | 1,263 | 1,315 | 1,186 | |
Organon & Co. — Total Assets ($M)($M) | 13,178 | 12,996 | 12,867 | 13,552 | 13,500 | 13,156 | 13,101 | 12,752 | 12,154 | 11,891 | 12,058 | 11,012 | |
Organon & Co. — Long-Term Debt ($M)($M) | 8,479 | 8,553 | 8,628 | 8,783 | 8,781 | 8,936 | 8,860 | 8,739 | 8,647 | 8,705 | 8,751 | 8,646 | |
Organon — Nexplanon / Implanon NXT (contraceptive implant) Worldwide sales ($M)($M)2 | 230,000,000 | 201,000,000 | 210,000,000 | 223,000,000 | 240,000,000 | 248,000,000 | 259,000,000 | 243,000,000 | 242,000,000 | 220,000,000 | 231,000,000 | 220,000,000 | |
Organon — Nexplanon / Implanon NXT (contraceptive implant) U.S. sales ($M)($M) | 129,000,000 | 127,000,000 | 124,000,000 | 146,000,000 | 163,000,000 | 176,000,000 | 175,000,000 | 172,000,000 | 171,000,000 | 153,000,000 | 154,000,000 | 146,000,000 | |
Organon — Nexplanon / Implanon NXT (contraceptive implant) International sales ($M)($M) | 101,000,000 | 74,000,000 | 86,000,000 | 77,000,000 | 77,000,000 | 72,000,000 | 84,000,000 | 70,000,000 | 70,000,000 | 67,000,000 | 76,000,000 | 74,000,000 | |
Organon — NuvaRing (contraceptive vaginal ring) Worldwide sales ($M)($M)2 | 27,000,000 | 24,000,000 | 16,000,000 | 26,000,000 | 28,000,000 | 22,000,000 | 25,000,000 | 23,000,000 | 29,000,000 | 38,000,000 | 39,000,000 | 43,000,000 | |
Organon — NuvaRing (contraceptive vaginal ring) U.S. sales ($M)($M) | 9,000,000 | 6,000,000 | -2,000,000 | 9,000,000 | 7,000,000 | 6,000,000 | 6,000,000 | 7,000,000 | 10,000,000 | 16,000,000 | 20,000,000 | 23,000,000 | |
Organon — NuvaRing (contraceptive vaginal ring) International sales ($M)($M) | 18,000,000 | 18,000,000 | 18,000,000 | 17,000,000 | 21,000,000 | 16,000,000 | 18,000,000 | 17,000,000 | 19,000,000 | 22,000,000 | 19,000,000 | 20,000,000 | |
Organon — Follistim AQ / Puregon (fertility) Worldwide sales ($M)($M)2 | 59,000,000 | 61,000,000 | 58,000,000 | 64,000,000 | 74,000,000 | 69,000,000 | 66,000,000 | 63,000,000 | 62,000,000 | 46,000,000 | 83,000,000 | 54,000,000 | |
Organon — Follistim AQ / Puregon (fertility) U.S. sales ($M)($M) | 17,000,000 | 21,000,000 | 23,000,000 | 24,000,000 | 30,000,000 | 35,000,000 | 25,000,000 | 26,000,000 | 22,000,000 | 11,000,000 | 51,000,000 | 22,000,000 | |
Organon — Follistim AQ / Puregon (fertility) International sales ($M)($M) | 43,000,000 | 39,000,000 | 35,000,000 | 40,000,000 | 43,000,000 | 34,000,000 | 39,000,000 | 37,000,000 | 40,000,000 | 35,000,000 | 31,000,000 | 32,000,000 | |
Organon — Marvelon / Mercilon (oral contraceptives) Worldwide sales ($M)($M)1 | 32,000,000 | 26,000,000 | 24,000,000 | 31,000,000 | 33,000,000 | 39,000,000 | 31,000,000 | 29,000,000 | 41,000,000 | 33,000,000 | 37,000,000 | 30,000,000 | |
Organon — Marvelon / Mercilon (oral contraceptives) International sales ($M)($M) | 32,000,000 | 26,000,000 | 24,000,000 | 31,000,000 | 33,000,000 | 39,000,000 | 31,000,000 | 29,000,000 | 41,000,000 | 33,000,000 | 37,000,000 | 30,000,000 | |
Organon — Jada System (postpartum hemorrhage device) Worldwide sales ($M)($M)2 | 0 | 5,000,000 | 20,000,000 | 20,000,000 | 18,000,000 | 15,000,000 | 18,000,000 | 16,000,000 | 14,000,000 | 13,000,000 | 12,000,000 | 13,000,000 | |
Organon — Jada System (postpartum hemorrhage device) U.S. sales ($M)($M) | 0 | 5,000,000 | 20,000,000 | 20,000,000 | 18,000,000 | 15,000,000 | 18,000,000 | 15,000,000 | 14,000,000 | 13,000,000 | 13,000,000 | 12,000,000 | |
Organon — Jada System (postpartum hemorrhage device) International sales ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M)($M)2 | 65,000,000 | 57,000,000 | 61,000,000 | 70,000,000 | 63,000,000 | 57,000,000 | 64,000,000 | 72,000,000 | 69,000,000 | 69,000,000 | 77,000,000 | 69,000,000 | |
Organon — Renflexis (infliximab-abda biosimilar) U.S. sales ($M)($M) | 44,000,000 | 42,000,000 | 42,000,000 | 51,000,000 | 46,000,000 | 44,000,000 | 52,000,000 | 56,000,000 | 56,000,000 | 55,000,000 | 62,000,000 | 57,000,000 | |
Organon — Renflexis (infliximab-abda biosimilar) International sales ($M)($M) | 21,000,000 | 15,000,000 | 20,000,000 | 19,000,000 | 17,000,000 | 12,000,000 | 12,000,000 | 16,000,000 | 13,000,000 | 14,000,000 | 14,000,000 | 12,000,000 | |
Organon — Ontruzant (trastuzumab-dttb biosimilar) Worldwide sales ($M)($M)2 | 6,000,000 | 5,000,000 | 19,000,000 | 31,000,000 | 31,000,000 | 18,000,000 | 34,000,000 | 20,000,000 | 48,000,000 | 39,000,000 | 62,000,000 | 40,000,000 | |
Organon — Ontruzant (trastuzumab-dttb biosimilar) U.S. sales ($M)($M) | 5,000,000 | 4,000,000 | 3,000,000 | 4,000,000 | 5,000,000 | 4,000,000 | 6,000,000 | 5,000,000 | 10,000,000 | 8,000,000 | 10,000,000 | 11,000,000 | |
Organon — Ontruzant (trastuzumab-dttb biosimilar) International sales ($M)($M) | 1,000,000 | 1,000,000 | 16,000,000 | 28,000,000 | 26,000,000 | 14,000,000 | 28,000,000 | 15,000,000 | 38,000,000 | 31,000,000 | 52,000,000 | 28,000,000 | |
Organon — Brenzys (etanercept biosimilar) Worldwide sales ($M)($M)1 | 14,000,000 | 20,000,000 | 21,000,000 | 23,000,000 | 22,000,000 | 14,000,000 | 14,000,000 | 27,000,000 | 12,000,000 | 24,000,000 | 28,000,000 | 13,000,000 | |
Organon — Brenzys (etanercept biosimilar) International sales ($M)($M) | 14,000,000 | 20,000,000 | 21,000,000 | 23,000,000 | 22,000,000 | 14,000,000 | 14,000,000 | 27,000,000 | 12,000,000 | 24,000,000 | 28,000,000 | 13,000,000 | |
Organon — Hadlima (adalimumab-bwwd biosimilar) Worldwide sales ($M)($M)1 | 79,000,000 | 67,000,000 | 69,000,000 | 63,000,000 | 50,000,000 | 47,000,000 | 44,000,000 | 40,000,000 | 28,000,000 | 30,000,000 | 24,000,000 | 8,000,000 | |
Organon — Hadlima (adalimumab-bwwd biosimilar) International sales ($M)($M) | 24,000,000 | 16,000,000 | 18,000,000 | 16,000,000 | 14,000,000 | 14,000,000 | 11,000,000 | 11,000,000 | 8,000,000 | 8,000,000 | 8,000,000 | 6,000,000 | |
Organon — Zetia (ezetimibe) Worldwide sales ($M)($M)2 | 96,000,000 | 87,000,000 | 90,000,000 | 93,000,000 | 74,000,000 | 85,000,000 | 77,000,000 | 81,000,000 | 75,000,000 | 84,000,000 | 69,000,000 | 69,000,000 | |
Organon — Zetia (ezetimibe) U.S. sales ($M)($M) | 2,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 3,000,000 | 2,000,000 | |
Organon — Zetia (ezetimibe) International sales ($M)($M) | 95,000,000 | 86,000,000 | 89,000,000 | 91,000,000 | 72,000,000 | 84,000,000 | 75,000,000 | 80,000,000 | 73,000,000 | 82,000,000 | 66,000,000 | 68,000,000 | |
Organon — Vytorin (ezetimibe/simvastatin) Worldwide sales ($M)($M)2 | 21,000,000 | 21,000,000 | 25,000,000 | 25,000,000 | 27,000,000 | 23,000,000 | 26,000,000 | 26,000,000 | 28,000,000 | 28,000,000 | 29,000,000 | 33,000,000 | |
Organon — Vytorin (ezetimibe/simvastatin) U.S. sales ($M)($M) | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | 1,000,000 | 2,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | |
Organon — Vytorin (ezetimibe/simvastatin) International sales ($M)($M) | 20,000,000 | 20,000,000 | 24,000,000 | 25,000,000 | 26,000,000 | 22,000,000 | 24,000,000 | 25,000,000 | 26,000,000 | 27,000,000 | 29,000,000 | 31,000,000 | |
Organon — Atozet (ezetimibe/atorvastatin) Worldwide sales ($M)($M)1 | 80,000,000 | 85,000,000 | 67,000,000 | 95,000,000 | 86,000,000 | 77,000,000 | 77,000,000 | 125,000,000 | 140,000,000 | 132,000,000 | 122,000,000 | 126,000,000 | |
Organon — Atozet (ezetimibe/atorvastatin) International sales ($M)($M) | 80,000,000 | 85,000,000 | 67,000,000 | 95,000,000 | 86,000,000 | 77,000,000 | 77,000,000 | 125,000,000 | 140,000,000 | 132,000,000 | 122,000,000 | 126,000,000 | |
Organon — Rosuzet (ezetimibe/rosuvastatin) Worldwide sales ($M)($M)1 | 5,000,000 | 6,000,000 | 8,000,000 | 6,000,000 | 6,000,000 | 4,000,000 | 13,000,000 | 11,000,000 | 9,000,000 | 16,000,000 | 18,000,000 | 17,000,000 | |
Organon — Rosuzet (ezetimibe/rosuvastatin) International sales ($M)($M) | 5,000,000 | 6,000,000 | 8,000,000 | 6,000,000 | 6,000,000 | 4,000,000 | 13,000,000 | 11,000,000 | 9,000,000 | 16,000,000 | 18,000,000 | 17,000,000 | |
Organon — Cozaar / Hyzaar (losartan) Worldwide sales ($M)($M)2 | 50,000,000 | 57,000,000 | 53,000,000 | 55,000,000 | 56,000,000 | 55,000,000 | 57,000,000 | 59,000,000 | 60,000,000 | 67,000,000 | 56,000,000 | 68,000,000 | |
Organon — Cozaar / Hyzaar (losartan) U.S. sales ($M)($M) | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 3,000,000 | 2,000,000 | 3,000,000 | |
Organon — Cozaar / Hyzaar (losartan) International sales ($M)($M) | 48,000,000 | 55,000,000 | 51,000,000 | 53,000,000 | 54,000,000 | 53,000,000 | 55,000,000 | 57,000,000 | 58,000,000 | 65,000,000 | 55,000,000 | 65,000,000 | |
Organon — Singulair (montelukast) Worldwide sales ($M)($M)2 | 48,000,000 | 40,000,000 | 59,000,000 | 53,000,000 | 66,000,000 | 74,000,000 | 84,000,000 | 85,000,000 | 93,000,000 | 98,000,000 | 114,000,000 | 91,000,000 | |
Organon — Singulair (montelukast) U.S. sales ($M)($M) | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 3,000,000 | 3,000,000 | |
Organon — Singulair (montelukast) International sales ($M)($M) | 46,000,000 | 38,000,000 | 57,000,000 | 51,000,000 | 64,000,000 | 72,000,000 | 82,000,000 | 83,000,000 | 90,000,000 | 95,000,000 | 111,000,000 | 88,000,000 | |
Organon — Nasonex (mometasone) Worldwide sales ($M)($M)2 | 58,000,000 | 65,000,000 | 65,000,000 | 60,000,000 | 66,000,000 | 72,000,000 | 76,000,000 | 63,000,000 | 60,000,000 | 77,000,000 | 69,000,000 | 60,000,000 | |
Organon — Nasonex (mometasone) U.S. sales ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Organon — Nasonex (mometasone) International sales ($M)($M) | 58,000,000 | 65,000,000 | 64,000,000 | 60,000,000 | 66,000,000 | 71,000,000 | 76,000,000 | 63,000,000 | 60,000,000 | 77,000,000 | 69,000,000 | 60,000,000 | |
Organon — Dulera (mometasone/formoterol) Worldwide sales ($M)($M)2 | 41,000,000 | 35,000,000 | 35,000,000 | 34,000,000 | 41,000,000 | 43,000,000 | 52,000,000 | 48,000,000 | 47,000,000 | 56,000,000 | 50,000,000 | 49,000,000 | |
Organon — Dulera (mometasone/formoterol) U.S. sales ($M)($M) | 30,000,000 | 23,000,000 | 24,000,000 | 24,000,000 | 32,000,000 | 34,000,000 | 42,000,000 | 38,000,000 | 39,000,000 | 43,000,000 | 40,000,000 | 40,000,000 | |
Organon — Dulera (mometasone/formoterol) International sales ($M)($M) | 11,000,000 | 12,000,000 | 11,000,000 | 10,000,000 | 9,000,000 | 10,000,000 | 11,000,000 | 10,000,000 | 8,000,000 | 13,000,000 | 10,000,000 | 9,000,000 | |
Organon — Clarinex (desloratadine) Worldwide sales ($M)($M)2 | 30,000,000 | 31,000,000 | 30,000,000 | 25,000,000 | 34,000,000 | 34,000,000 | 27,000,000 | 27,000,000 | 35,000,000 | 37,000,000 | 29,000,000 | 28,000,000 | |
Organon — Clarinex (desloratadine) U.S. sales ($M)($M) | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | |
Organon — Clarinex (desloratadine) International sales ($M)($M) | 30,000,000 | 30,000,000 | 29,000,000 | 25,000,000 | 33,000,000 | 34,000,000 | 28,000,000 | 26,000,000 | 35,000,000 | 36,000,000 | 29,000,000 | 26,000,000 | |
Organon — Arcoxia (etoricoxib) Worldwide sales ($M)($M)1 | 69,000,000 | 59,000,000 | 70,000,000 | 71,000,000 | 63,000,000 | 62,000,000 | 59,000,000 | 69,000,000 | 68,000,000 | 75,000,000 | 50,000,000 | 64,000,000 | |
Organon — Arcoxia (etoricoxib) International sales ($M)($M) | 69,000,000 | 59,000,000 | 70,000,000 | 71,000,000 | 63,000,000 | 62,000,000 | 59,000,000 | 69,000,000 | 68,000,000 | 75,000,000 | 50,000,000 | 64,000,000 | |
Organon — Fosamax (alendronate) Worldwide sales ($M)($M)2 | 25,000,000 | 29,000,000 | 36,000,000 | 40,000,000 | 34,000,000 | 33,000,000 | 39,000,000 | 38,000,000 | 35,000,000 | 40,000,000 | 36,000,000 | 41,000,000 | |
Organon — Fosamax (alendronate) U.S. sales ($M)($M) | 1,000,000 | 0 | 0 | 0 | 0 | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |
Organon — Fosamax (alendronate) International sales ($M)($M) | 24,000,000 | 29,000,000 | 35,000,000 | 40,000,000 | 34,000,000 | 32,000,000 | 38,000,000 | 37,000,000 | 34,000,000 | 38,000,000 | 35,000,000 | 40,000,000 | |
Organon — Diprospan (betamethasone) Worldwide sales ($M)($M)1 | 44,000,000 | 35,000,000 | 38,000,000 | 41,000,000 | 41,000,000 | 30,000,000 | 37,000,000 | 37,000,000 | 37,000,000 | 29,000,000 | 33,000,000 | 31,000,000 | |
Organon — Diprospan (betamethasone) International sales ($M)($M) | 44,000,000 | 35,000,000 | 38,000,000 | 41,000,000 | 41,000,000 | 30,000,000 | 37,000,000 | 37,000,000 | 37,000,000 | 29,000,000 | 33,000,000 | 31,000,000 | |
Organon — Proscar (finasteride — BPH) Worldwide sales ($M)($M)2 | 20,000,000 | 26,000,000 | 24,000,000 | 27,000,000 | 22,000,000 | 24,000,000 | 22,000,000 | 23,000,000 | 23,000,000 | 26,000,000 | 20,000,000 | 25,000,000 | |
Organon — Proscar (finasteride — BPH) U.S. sales ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Organon — Proscar (finasteride — BPH) International sales ($M)($M) | 20,000,000 | 26,000,000 | 23,000,000 | 27,000,000 | 22,000,000 | 24,000,000 | 22,000,000 | 23,000,000 | 23,000,000 | 26,000,000 | 20,000,000 | 25,000,000 | |
Organon — Propecia (finasteride — alopecia) Worldwide sales ($M)($M)2 | 36,000,000 | 30,000,000 | 28,000,000 | 33,000,000 | 32,000,000 | 26,000,000 | 32,000,000 | 28,000,000 | 28,000,000 | 23,000,000 | 33,000,000 | 22,000,000 | |
Organon — Propecia (finasteride — alopecia) U.S. sales ($M)($M) | 2,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | |
Organon — Propecia (finasteride — alopecia) International sales ($M)($M) | 34,000,000 | 28,000,000 | 26,000,000 | 31,000,000 | 30,000,000 | 24,000,000 | 31,000,000 | 27,000,000 | 27,000,000 | 21,000,000 | 32,000,000 | 21,000,000 | |
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) Worldwide sales ($M)($M)2 | 35,000,000 | 25,000,000 | 39,000,000 | 34,000,000 | 31,000,000 | 24,000,000 | 12,000,000 | 0 | 0 | 0 | |||
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) U.S. sales ($M)($M) | 34,000,000 | 23,000,000 | 31,000,000 | 31,000,000 | 29,000,000 | 20,000,000 | 10,000,000 | 0 | 0 | 0 | |||
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) International sales ($M)($M) | 1,000,000 | 2,000,000 | 8,000,000 | 3,000,000 | 2,000,000 | 4,000,000 | 1,000,000 | 0 | 0 | 0 | |||
U.S. Real Personal Consumption Expenditures — Health Care (SAAR, $B Chained 2017 Dollars) | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | 3,079.00 | |
DB Segment Context — Pharmaceutical Segment Revenue ($M)($M)4 | 14,760 | 14,349 | 14,843 | 15,611 | 14,050 | 13,638 | 14,042 | 14,943 | 14,408 | 14,006 | 13,141 | 14,263 | |
Pharmaceutical Segment — Cost of Sales ($M)($M) | 1,731 | 1,553 | 1,841 | 1,664 | 1,601 | 1,573 | 1,509 | 1,904 | 1,708 | 1,706 | |||
Pharmaceutical Segment — SG&A Expense ($M)($M) | 1,437 | 1,332 | 1,547 | 1,469 | 1,367 | 1,402 | 1,666 | 1,519 | 1,514 | 1,429 | |||
Animal Health Segment — Cost of Sales ($M)($M) | 715 | 675 | 681 | 710 | 659 | 600 | 631 | 613 | 612 | 613 | |||
Animal Health Segment — SG&A Expense ($M)($M) | 304 | 282 | 303 | 277 | 284 | 260 | 293 | 268 | 270 | 252 | |||
DB Geographic Context — Consolidated U.S. Revenue ($M)($M)7 | 9,367 | 9,164 | 9,139 | 10,012 | 8,836 | 8,522 | 8,188 | 8,736 | 7,876 | 7,478 | 7,087 | 7,715 | |
Geographic Long-Lived Assets — United States ($M)($M) | 15,291 | 15,097 | 15,021 | 15,482 | 15,182 | 14,891 | 14,724 | 13,915 | |||||
Geographic Long-Lived Assets — EMEA ($M)($M) | 9,076 | 8,966 | 8,856 | 8,665 | 8,554 | 8,402 | 7,548 | 7,562 | |||||
Geographic Long-Lived Assets — China ($M)($M) | 210 | 213 | 218 | 208 | 204 | 198 | 202 | 193 | |||||
Geographic Long-Lived Assets — Japan ($M)($M) | 129 | 136 | 144 | 147 | 144 | 145 | 143 | 133 | |||||
Geographic Long-Lived Assets — Asia Pacific ($M)($M) | 850 | 842 | 898 | 948 | 966 | 973 | 982 | 1,022 | |||||
Geographic Long-Lived Assets — Latin America ($M)($M) | 131 | 128 | 128 | 139 | 135 | 135 | 133 | 222 | |||||
Geographic Long-Lived Assets — Other Countries ($M)($M) | 50 | 51 | 51 | 50 | 51 | 49 | 47 | 4 | |||||
DB Income Statement — Consolidated Sales / Revenue ($M)($M)17 | 16,607 | 16,286 | 16,400 | 17,276 | 15,806 | 15,529 | 15,624 | 16,657 | 16,112 | 15,775 | 14,630 | 15,962 | |
Cost of Sales ($M)($M) | 4,395 | 4,195 | 5,551 | 3,855 | 3,557 | 3,419 | 3,828 | 4,080 | 3,745 | 3,540 | 3,912 | 4,264 | |
Selling, General and Administrative (SG&A) ($M)($M) | 2,904 | 2,700 | 2,898 | 2,633 | 2,649 | 2,552 | 2,864 | 2,731 | 2,739 | 2,483 | 2,804 | 2,519 | |
Research and Development (R&D) ($M)($M) | 9,741 | 12,592 | 3,886 | 4,234 | 4,048 | 3,621 | 4,584 | 5,862 | 3,500 | 3,992 | 9,627 | 3,307 | |
Restructuring Costs ($M)($M) | 151 | 195 | 213 | 47 | 560 | 69 | 51 | 56 | 80 | 123 | 255 | 126 | |
Other (Income) Expense, Net ($M)($M) | -99 | -138 | -432 | 238 | 7 | 35 | -127 | 162 | -42 | 33 | -78 | -126 | |
Interest Income ($M)($M) | 35 | 35 | 69 | 96 | 69 | 109 | 146 | 127 | 69 | 73 | 70 | 73 | |
Interest Expense ($M)($M) | 525 | 479 | 411 | 327 | 305 | 313 | 328 | 330 | 310 | 303 | 310 | 317 | |
Gain (Loss) on Equity Investments ($M)($M) | 242 | 168 | -195 | 373 | 100 | 90 | -155 | -31 | 56 | 143 | 100 | -33 | |
Income Before Taxes ($M)($M) | -683 | -3,534 | 3,420 | 6,745 | 4,999 | 5,903 | 4,170 | 4,090 | 6,006 | 5,670 | -2,046 | 5,620 | |
Taxes on Income ($M)($M) | 654 | 709 | 458 | 958 | 571 | 818 | 426 | 929 | 545 | 903 | -820 | 870 | |
Less: Net Income Attributable to Noncontrolling Interests ($M)($M) | -2 | -3 | -1 | 2 | 1 | 6 | 1 | 4 | 6 | 5 | 0 | 5 | |
Net Income Attributable to Merck & Co., Inc. ($M)($M) | -1,335 | -4,240 | 2,963 | 5,785 | 4,427 | 5,079 | 3,743 | 3,157 | 5,455 | 4,762 | -1,226 | 4,745 | |
Basic EPS ($)($) | -0.54 | -1.72 | 2.32 | 1.76 | 2.01 | 1.25 | 2.15 | 1.88 | 1.87 | ||||
Diluted EPS ($)($) | -0.54 | -1.72 | 2.32 | 1.76 | 2.01 | 1.24 | 2.14 | 1.87 | 1.86 | ||||
Weighted-Average Basic Shares (M) | 2,470.00 | 2,472.00 | 2,495.00 | 2,510.00 | 2,523.00 | 2,534.00 | 2,534.00 | 2,533.00 | 2,537.00 | ||||
Weighted-Average Diluted Shares (M) | 2,470.00 | 2,472.00 | 2,498.00 | 2,513.00 | 2,531.00 | 2,541.00 | 2,544.00 | 2,544.00 | 2,546.00 | ||||
Dividends Declared per Common Share ($)($) | 0.85 | 0.85 | 0.85 | 0.81 | 0.81 | 0.81 | 0.81 | 0.77 | 0.77 | 0.77 | 0.77 | 0.73 | |
DB Balance Sheet — Total Assets ($M)($M)27 | 129,802 | 128,685 | 136,866 | 129,546 | 117,523 | 115,122 | 117,106 | 117,532 | 112,630 | 105,849 | 106,675 | 106,727 | |
Cash and Cash Equivalents ($M)($M) | 6,849 | 5,327 | 14,565 | 18,169 | 8,073 | 8,732 | 13,318 | 14,688 | 11,373 | 5,671 | 6,909 | 8,669 | |
Short-Term Investments ($M)($M) | 292 | 375 | 0 | 45 | 615 | 599 | 447 | 0 | 50 | 40 | 252 | 168 | |
Accounts Receivable, Net ($M)($M)1 | 12,564 | 12,210 | 11,775 | 12,120 | 11,846 | 10,790 | 10,278 | 11,381 | 11,642 | 11,366 | 10,349 | 10,394 | |
Allowance for Doubtful Accounts ($M)($M) | 108 | 103 | 97 | 93 | 94 | 93 | 89 | 79 | 82 | 80 | 88 | 85 | |
Inventories ($M)($M) | 6,207 | 6,479 | 6,658 | 6,444 | 6,601 | 6,196 | 6,109 | 6,244 | 6,469 | 6,510 | 6,358 | 6,131 | |
Other Current Assets ($M)($M) | 10,767 | 10,624 | 10,518 | 10,779 | 9,996 | 9,289 | 8,706 | 8,143 | 8,740 | 7,950 | 8,368 | 6,656 | |
Total Current Assets ($M)($M) | 36,679 | 35,015 | 43,516 | 47,557 | 37,065 | 35,503 | 38,782 | 40,361 | 38,205 | 31,445 | 32,168 | 31,954 | |
Property, Plant and Equipment (PP&E), Net ($M)($M)1 | 25,737 | 25,433 | 25,316 | 25,639 | 25,236 | 24,793 | 23,779 | 23,446 | 23,221 | 23,045 | 23,051 | 22,526 | |
PP&E — Less Allowance for Depreciation ($M)($M) | -22,729 | -22,288 | -21,914 | -20,605 | -20,256 | -19,680 | -19,155 | -19,072 | -18,960 | -18,620 | -18,266 | -18,446 | |
Goodwill ($M)($M) | 21,582 | 21,581 | 21,579 | 21,587 | 21,591 | 21,684 | 21,668 | 21,697 | 21,161 | 21,181 | 21,197 | 21,183 | |
Other Intangibles, Net ($M)($M) | 24,978 | 25,745 | 26,681 | 15,313 | 15,193 | 15,758 | 16,370 | 17,010 | 16,984 | 17,572 | 18,011 | 19,199 | |
Long-Term Investments ($M)($M) | 1,222 | 1,105 | 956 | 1,117 | 774 | 616 | 463 | 575 | 357 | 280 | 252 | 1,306 | |
Other Noncurrent Assets ($M)($M) | 19,604 | 19,806 | 18,818 | 18,333 | 17,664 | 16,768 | 16,044 | 14,443 | 12,702 | 12,326 | 11,996 | 10,559 | |
Trade Accounts Payable ($M)($M) | 3,827 | 3,863 | 4,404 | 4,147 | 3,892 | 3,784 | 4,079 | 3,586 | 3,519 | 3,514 | 3,922 | 3,509 | |
Loans Payable and Current Portion of Long-Term Debt ($M)($M) | 2,825 | 2,444 | 2,589 | 1,405 | 1,434 | 1,360 | 2,649 | 3,149 | 3,071 | 3,077 | 1,372 | 887 | |
Income Taxes Payable ($M)($M) | 4,224 | 3,946 | 4,726 | 4,848 | 4,156 | 5,181 | 3,914 | 4,330 | 2,777 | 2,398 | 2,649 | 1,981 | |
Accrued and Other Current Liabilities ($M)($M) | 14,725 | 14,549 | 14,468 | 16,186 | 14,502 | 12,772 | 15,694 | 16,539 | 14,712 | 14,102 | 15,766 | 14,840 | |
Total Current Liabilities ($M)($M) | 27,731 | 26,945 | 28,327 | 28,628 | 26,037 | 25,174 | 28,420 | 29,586 | 26,060 | 25,099 | 25,694 | 23,094 | |
Long-Term Debt ($M)($M) | 51,081 | 46,673 | 46,750 | 39,969 | 33,968 | 33,484 | 34,462 | 34,982 | 34,717 | 31,142 | 33,683 | 33,972 | |
Deferred Income Taxes ($M)($M) | 1,433 | 1,494 | 1,439 | 1,381 | 1,427 | 1,409 | 1,387 | 864 | 876 | 922 | 871 | 1,018 | |
Other Noncurrent Liabilities ($M)($M) | 7,573 | 7,642 | 7,688 | 7,661 | 7,031 | 6,655 | 6,465 | 7,540 | 7,329 | 8,262 | 8,792 | 7,343 | |
Common Stock ($M)($M) | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | 1,788 | |
Other Paid-In Capital ($M)($M) | 44,950 | 45,176 | 45,029 | 44,832 | 44,644 | 44,816 | 44,704 | 44,530 | 44,362 | 44,598 | 44,509 | 44,358 | |
Retained Earnings ($M)($M) | 63,269 | 66,721 | 73,075 | 72,231 | 68,477 | 66,097 | 63,069 | 61,384 | 60,187 | 56,697 | 53,895 | 57,082 | |
Accumulated Other Comprehensive Loss ($M)($M) | -3,942 | -4,060 | -4,287 | -5,202 | -5,421 | -4,965 | -4,945 | -5,371 | -5,361 | -5,274 | -5,161 | -4,916 | |
Treasury Stock, at Cost ($M)($M) | -64,132 | -63,747 | -62,999 | -61,799 | -60,495 | -59,401 | -58,303 | -57,829 | -57,394 | -57,445 | -57,450 | -57,066 | |
Merck & Co., Inc. Stockholders' Equity ($M)($M) | 41,933 | 45,878 | 52,606 | 51,850 | 48,993 | 48,335 | 46,313 | 44,502 | 43,582 | 40,364 | 37,581 | 41,246 | |
Noncontrolling Interests ($M)($M) | 51 | 53 | 56 | 57 | 67 | 65 | 59 | 58 | 66 | 60 | 54 | 54 | |
Total Equity ($M)($M) | 41,984 | 45,931 | 52,662 | 51,907 | 49,060 | 48,400 | 46,372 | 44,560 | 43,648 | 40,424 | 37,635 | 41,300 | |
DB Cash Flow — Operating Cash Flow ($M)($M)14 | 5,370 | 3,918 | 2,857 | 7,822 | 3,293 | 2,500 | 3,450 | 9,291 | 5,637 | 3,090 | 246 | 7,717 | |
Capital Expenditures ($M)($M) | 893 | 991 | 1,033 | 987 | 764 | 1,328 | 937 | 783 | 791 | 861 | 989 | 902 | |
Depreciation and Amortization ($M)($M) | 599 | 581 | 1,448 | 532 | 518 | 502 | 518 | 553 | 518 | 511 | 474 | 452 | |
Stock-Based Compensation ($M)($M) | 298 | 185 | 205 | 204 | 216 | 195 | 187 | 195 | 203 | 176 | 167 | 164 | |
Deferred Income Taxes ($M)($M) | -544 | -315 | -825 | -212 | -448 | -186 | -616 | -401 | -181 | -51 | -931 | -336 | |
Acquisitions of Businesses, Net of Cash Acquired ($M)($M) | 0 | -8,779 | -10,042 | 0 | 0 | 0 | 1,344 | -598 | 0 | -746 | 0 | 0 | |
Purchases of Securities and Other Investments ($M)($M) | -148 | -374 | 0 | 0 | -612 | -595 | -455 | 0 | -49 | -15 | -251 | -117 | |
Net Cash Used in Investing Activities ($M)($M) | -5,602 | -10,210 | -11,201 | -283 | -770 | -1,487 | -1,444 | -3,845 | -1,069 | -1,376 | 53 | -334 | |
Payments on Debt ($M)($M) | -5 | -1,140 | -2 | -1 | 0 | -2,500 | -539 | 0 | 0 | -751 | -3 | -1 | |
Dividends Paid to Stockholders ($M)($M) | -2,144 | -2,105 | -2,018 | -2,031 | -2,077 | -2,050 | -1,951 | -1,953 | -1,986 | -1,950 | -1,852 | -1,855 | |
Purchases of Treasury Stock ($M)($M) | -757 | -874 | -1,252 | -1,323 | -1,345 | -1,164 | -489 | -444 | -251 | -122 | -393 | -466 | |
Net Cash Used in Financing Activities ($M)($M) | 1,762 | -2,981 | 4,751 | 2,638 | -3,556 | -5,755 | -3,009 | -2,425 | 1,216 | -2,814 | -2,245 | -4,269 | |
Effect of Exchange Rate Changes on Cash ($M)($M) | -37 | -19 | 23 | 10 | 374 | 156 | -367 | 294 | -82 | -138 | 186 | -157 | |
Net Increase (Decrease) in Cash and Cash Equivalents ($M)($M) | 1,493 | -9,292 | -3,570 | 10,187 | -659 | -4,586 | -1,370 | 3,315 | 5,702 | -1,238 | -1,760 | 2,957 | |
Cash Paid for Interest ($M)($M) | 654 | 342 | 451 | 233 | 383 | 233 | 478 | 241 | 364 | 217 | 422 | 229 | |
252 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Merck & Co., Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Merck reports two operating segments — Pharmaceutical and Animal Health — while commercial performance is driven by brand-level Worldwide / U.S. / International sales across Oncology, Vaccines, Cardiopulmonary & Hospital Acute Care, Virology, Diabetes, and Animal Health.
- Core commercial, GTN & R&D KPIs (Groups 1–7) cover: (1) Oncology Portfolio (Keytruda $8,229M WW / $5,088M U.S. / $3,141M Intl in Q2 2026 and $31,680M in FY25; subcutaneous Keytruda Qlex $226M in Q2 2026; Welireg $228M in Q2 2026; Lynparza alliance $398M; Lenvima alliance $273M; Reblozyl royalty $164M; Koselugo alliance $62M); (2) Vaccines Portfolio ($22,554M Total Vaccines in FY25; Gardasil/Gardasil 9 $1,089M in Q2 2026 & China sales breakdown; ProQuad/M-M-R II/Varivax $652M in Q2 2026 with individual Varivax $400M, ProQuad $247M & M-M-R II $119M in Q2 2026 and Q4 = FY − 9M split; Vaxneuvance $262M; Capvaxive $207M; RotaTeq $157M; Pneumovax 23 $35M); (3) Cardiopulmonary, Respiratory & Hospital Acute Care (Winrevair $467M in Q2 2026 / $1,443M in FY25; Ohtuvayre $171M in Q2 2026 following the Verona Pharma acquisition; Adempas/Verquvo Bayer alliance $176M & direct Adempas $85M; Bridion $470M; Prevymis $268M; Dificid; Zerbaxa); (4) Diabetes, Virology & Immunology (Total Diabetes $2,442M in FY25 across Januvia & Janumet; Lagevrio; Isentress; Delstrigo; Pifeltro; Simponi; Remicade; Belsomra; plus pre-spin legacy brands); (5) Animal Health ($1,775M in Q2 2026 / $6,354M in FY25 across Livestock $1,009M and Companion Animal $766M, including Bravecto $396M in Q2 2026 / $1.2B in FY25) & 9-region Pharmaceutical Geographic Sales ($M and % share); (6) U.S. Gross-to-Net (GTN) Customer Discounts Rollforward ($3,907M ending accrual at FY25; $21,375M FY25 provision; $21,150M payments; $2,500M in Q2 2026), 6 Strategic Alliances (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback), and R&D Breakdown (MRL Direct $11.5B vs. Animal Health/BD/Support $6.4B in FY25); and (7) GAAP vs. Non-GAAP Reconciliation, Other (Income) Expense breakdown, and 2024 & 2019 Restructuring Programs.
- Groups 8–11 cover: (8) Inventories by stage ($12,588M total net current & noncurrent at Q2 2026: Current $6,207M, Long-Term $5,900M, Pre-Launch, Finished Goods $2,186M, Raw Materials & WIP $11,194M, Supplies $309M, LIFO Reserve $1,101M), Drug-Specific Net Intangible Assets (Winrevair $9,424M, Bridion $1,949M, Adempas $203M at Q2 2026), Operating Leases, Defined Benefit Pension & OPEB Plans, and Income Tax / UTB Rollforward ($2,500M UTB at FY25); (9) Global Workforce (30,451 U.S. / 43,722 Non-U.S. employees, 8.5% overall / 5.4% voluntary turnover in FY25), Form 11-K across 3 employee benefit plans (Merck US Savings Plan $13,205M, Puerto Rico Savings Plan $155M, ESPP $376M net assets at FY25, plus Master Trust asset classes), Form SD 3TG Smelters (222 identified / 159 RMAP-conformant in FY25), and Merck Impact Report ESG metrics (48.6M people reached with social investments, 94.3% OTIF, Scope 1/2/3 GHG, energy, water, waste); (10) Spun-Off Subsidiary Self-Disclosed Data for Organon & Co. (NYSE: OGN, CIK 0001821825, spun off June 2, 2021 — P&L, balance sheet, geography, and 24 Women's Health, Biosimilar & Established Brands); and (11) FRED Pharmaceutical & Healthcare Macro Benchmarks and Postgres DB Segment & Financial Statement Context.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (15)
- Animal Health (Livestock, Companion Animal, Bravecto) & Pharmaceutical Regions › Animal Health Segment — Worldwide Sales ($M) › Animal Health — Companion Animal (Vaccines & Parasiticides) — Worldwide Sales ($M) › Bravecto (Fluralaner Parasiticides Line) — Quarterly Sales Q1–Q3 ($M; Q4 Not Separately Disclosed) › Bravecto — Worldwide Constant-Currency (Ex-Exchange) Growth YoY (%)
- Animal Health (Livestock, Companion Animal, Bravecto) & Pharmaceutical Regions › Pharmaceutical Segment — Worldwide Sales ($M) › Pharmaceutical Segment — Total International Sales ($M) › Pharmaceutical Segment — International Reported Growth YoY (%)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) › AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Noncurrent Liabilities to Partner ($M)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current Payables / Liabilities to Partner ($M)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Noncurrent Liabilities to Partner ($M)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) › Eisai Co., Ltd. (Lenvima Oncology Alliance) — Intangible Asset Amortization in Cost of Sales ($M)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M) › Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Noncurrent Liabilities to Partner ($M)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) › Daiichi Sankyo (3 DXd ADC Oncology Programs) — Noncurrent Liabilities to Partner ($M)
- Gross-to-Net Discounts (U.S. GTN Rollforward), Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure › Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M) › Ridgeback (Lagevrio) — R&D Reimbursement from Partner ($M)
- GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in SG&A ($M)
- GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) › 2024 Restructuring Program (Supply Network & Commercial Optimization) — Recorded in R&D ($M)
- GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs) › Restructuring Programs — Total Period Charges Across All Programs ($M) › 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) › 2019 Restructuring Program (legacy) — Cumulative Charges Incurred Since Inception ($M)
- Non-Pharma Sources (FRED Benchmarks) & Segments & Financial Statements › Income Statement — Consolidated Sales / Revenue ($M) › Income from Continuing Operations ($M)
- Non-Pharma Sources (FRED Benchmarks) & Segments & Financial Statements › Cash Flow — Operating Cash Flow ($M) › Proceeds from Sales of Securities and Other Investments ($M)
- Non-Pharma Sources (FRED Benchmarks) & Segments & Financial Statements › Cash Flow — Operating Cash Flow ($M) › Net Change in Short-Term Borrowings ($M)
Dữ liệu cập nhật 2026-10-26.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Oncology Portfolio (Keytruda, Keytruda Qlex, Welireg & Oncology Alliances)
- Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M) ($M)42 kỳ
- Welireg (belzutifan — HIF-2α inhibitor) — Worldwide sales ($M) ($M)18 kỳ
- Lynparza (olaparib — AstraZeneca oncology alliance revenue) — Worldwide sales ($M) ($M)38 kỳ
- Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M) ($M)37 kỳ
- Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M) ($M)22 kỳ
- Koselugo (selumetinib — AstraZeneca NF1 alliance revenue) — Worldwide ($M) ($M)16 kỳ
- Temodar (temozolomide, legacy) — Worldwide sales ($M) ($M)8 kỳ
- Emend (aprepitant/fosaprepitant — CINV supportive care, legacy) — Worldwide sales ($M) ($M)16 kỳ
Vaccines Portfolio (Gardasil, Pediatric Vaccines, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23)
- Total Vaccines Franchise — Worldwide sales ($M) ($M)18 kỳ
- Gardasil / Gardasil 9 (HPV recombinant vaccine) — Worldwide sales ($M) ($M)38 kỳ
- ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M) ($M)38 kỳ
- Vaxneuvance (15-valent pneumococcal conjugate vaccine) — Worldwide sales ($M) ($M)18 kỳ
- Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M) ($M)10 kỳ
- RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide sales ($M) ($M)42 kỳ
- Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) — Worldwide sales ($M) ($M)10 kỳ
- Vaqta (hepatitis A vaccine, legacy) — Worldwide sales ($M) ($M)24 kỳ
- Zostavax (zoster vaccine live, legacy) — Worldwide sales ($M) ($M)8 kỳ
Cardiovascular, Pulmonary, Respiratory & Hospital Acute Care (Winrevair, Ohtuvayre, Adempas/Verquvo, Bridion, Prevymis, Dificid, Zerbaxa)
- Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M) ($M)13 kỳ
- Ohtuvayre (ensifentrine — COPD maintenance therapy, acquired via Verona Pharma Q4 2025) — Worldwide sales ($M) ($M)4 kỳ
- Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide sales ($M) ($M)30 kỳ
- Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide sales ($M) ($M)42 kỳ
- Prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M) ($M)30 kỳ
- Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M)22 kỳ
- Zerbaxa (ceftolozane and tazobactam) — Worldwide sales ($M) ($M)30 kỳ
- Primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M) ($M)32 kỳ
- Cancidas (caspofungin, legacy) — Worldwide sales ($M) ($M)28 kỳ
- Noxafil (posaconazole, legacy) — Worldwide sales ($M) ($M)36 kỳ
- Invanz (ertapenem, legacy) — Worldwide sales ($M) ($M)28 kỳ
- Cubicin (daptomycin, legacy) — Worldwide sales ($M) ($M)20 kỳ
Diabetes, Virology, Immunology & Pre-Organon Legacy Brands
- Total Diabetes Franchise (Januvia + Janumet) — Worldwide sales ($M) ($M)9 kỳ
- Lagevrio (molnupiravir — COVID-19 oral antiviral, Ridgeback alliance) — Worldwide sales ($M) ($M)22 kỳ
- Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — Worldwide sales ($M) ($M)38 kỳ
- Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M) ($M)14 kỳ
- Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M) ($M)12 kỳ
- Zepatier (elbasvir and grazoprevir — HCV, legacy) — Worldwide sales ($M) ($M)20 kỳ
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)40 kỳ
- Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)40 kỳ
- Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M) ($M)36 kỳ
- Other Pharmaceutical Products — Worldwide sales ($M) ($M)42 kỳ
- Singulair (montelukast, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
- Cozaar / Hyzaar (losartan, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)17 kỳ
- Zetia (ezetimibe, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
- Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
- Atozet (ezetimibe/atorvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)17 kỳ
- Arcoxia (etoricoxib, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
- Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)12 kỳ
- Nasonex (mometasone, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
- Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)8 kỳ
- NuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
- Implanon / Nexplanon (etonogestrel implant, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)17 kỳ
- Follistim AQ (follitropin beta, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)21 kỳ
Animal Health (Livestock, Companion Animal, Bravecto) & Pharmaceutical Regions
Gross-to-Net Discounts (U.S. GTN Rollforward), Alliances & Collaborations (AstraZeneca, Eisai, Bayer, Daiichi Sankyo, Moderna, Ridgeback) & R&D Structure
- U.S. Aggregate Customer Discounts (Chargebacks & Rebates) Provision ($M) ($M)38 kỳ
- U.S. Chargebacks & Rebates Accrual Rollforward — Ending Balance ($M) ($M)10 kỳ
- Collaboration — AstraZeneca (Lynparza & Koselugo Oncology Alliance) ($M) ($M)32 kỳ
- Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) ($M)34 kỳ
- Collaboration — Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) ($M) ($M)30 kỳ
- Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M)14 kỳ
- Collaboration — Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) ($M) ($M)14 kỳ
- Collaboration — Ridgeback Biotherapeutics (Lagevrio Antiviral Alliance) ($M) ($M)22 kỳ
- Research & Development Expense — Pharmaceutical Segment ($M) ($M)10 kỳ
GAAP vs. Non-GAAP Reconciliation (Table 2a), Other Income/Expense (Table 4) & Restructuring Programs (2024 & 2019 Programs)
Inventories by Stage & Pre-Launch, Intangible Assets by Drug, Operating Leases, Pensions & Taxes
- Total Inventories — Current & Noncurrent Net ($M) ($M)36 kỳ
- Finite-Lived Intangible Assets — Products & Developed Technology, Net ($M) ($M)4 kỳ
- Operating Leases — Right-of-Use (ROU) Assets ($M) ($M)7 kỳ
- U.S. Defined Benefit Pension Plans — Funded Status ($M) ($M)10 kỳ
- International Defined Benefit Pension Plans — Funded Status ($M) ($M)10 kỳ
- Other Postretirement Benefit (OPEB) Plans — Funded Status ($M) ($M)10 kỳ
- Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M)10 kỳ
- Environmental Remediation & Compliance Accrual ($M) ($M)10 kỳ
Global Headcount (DEF 14A), Employee Savings Plans (Form 11-K — 3 Plans & Master Trust), Conflict Minerals (Form SD) & Sustainability (Merck Impact Report)
- U.S. Employees (headcount)7 kỳ
- Merck US Savings Plan (Form 11-K) — Net Assets Available for Benefits ($M) ($M)9 kỳ
- MSD Puerto Rico Savings & Security Plan (Form 11-K) — Net Assets Available for Benefits ($M) ($M)9 kỳ
- MSD Employee Stock Purchase Plan (Form 11-K) — Net Assets Available for Benefits ($M) ($M)9 kỳ
- Merck Master Trust — Registered Investment Companies (Mutual Funds) ($M) ($M)8 kỳ
- Access to Health — People Reached with Social Investments (millions)5 kỳ
- Product Supply Chain — Orders Delivered On-Time and In-Full (OTIF) (%) (%)6 kỳ
- Operational GHG Emissions — Total Scope 1 + Scope 2 Market-Based (metric tons CO2e)6 kỳ
Spun-Off Entity Filings — Organon & Co. (NYSE: OGN, CIK 0001821825 — Women's Health, Biosimilars & Established Brands)
- Organon & Co. — Total Revenues ($M) ($M)26 kỳ
- Organon — Nexplanon / Implanon NXT (contraceptive implant) Worldwide sales ($M) ($M)22 kỳ
- Organon — NuvaRing (contraceptive vaginal ring) Worldwide sales ($M) ($M)22 kỳ
- Organon — Follistim AQ / Puregon (fertility) Worldwide sales ($M) ($M)22 kỳ
- Organon — Marvelon / Mercilon (oral contraceptives) Worldwide sales ($M) ($M)18 kỳ
- Organon — Jada System (postpartum hemorrhage device) Worldwide sales ($M) ($M)16 kỳ
- Organon — Renflexis (infliximab-abda biosimilar) Worldwide sales ($M) ($M)22 kỳ
- Organon — Ontruzant (trastuzumab-dttb biosimilar) Worldwide sales ($M) ($M)22 kỳ
- Organon — Brenzys (etanercept biosimilar) Worldwide sales ($M) ($M)22 kỳ
- Organon — Hadlima (adalimumab-bwwd biosimilar) Worldwide sales ($M) ($M)22 kỳ
- Organon — Zetia (ezetimibe) Worldwide sales ($M) ($M)22 kỳ
- Organon — Vytorin (ezetimibe/simvastatin) Worldwide sales ($M) ($M)22 kỳ
- Organon — Atozet (ezetimibe/atorvastatin) Worldwide sales ($M) ($M)22 kỳ
- Organon — Rosuzet (ezetimibe/rosuvastatin) Worldwide sales ($M) ($M)22 kỳ
- Organon — Cozaar / Hyzaar (losartan) Worldwide sales ($M) ($M)22 kỳ
- Organon — Singulair (montelukast) Worldwide sales ($M) ($M)22 kỳ
- Organon — Nasonex (mometasone) Worldwide sales ($M) ($M)22 kỳ
- Organon — Dulera (mometasone/formoterol) Worldwide sales ($M) ($M)22 kỳ
- Organon — Clarinex (desloratadine) Worldwide sales ($M) ($M)22 kỳ
- Organon — Arcoxia (etoricoxib) Worldwide sales ($M) ($M)22 kỳ
- Organon — Fosamax (alendronate) Worldwide sales ($M) ($M)22 kỳ
- Organon — Diprospan (betamethasone) Worldwide sales ($M) ($M)22 kỳ
- Organon — Proscar (finasteride — BPH) Worldwide sales ($M) ($M)22 kỳ
- Organon — Propecia (finasteride — alopecia) Worldwide sales ($M) ($M)22 kỳ
- Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) Worldwide sales ($M) ($M)10 kỳ
External Pharmaceutical Industry Sources (FRED Benchmarks) & Segment / Financial Statements Context
- U.S. Producer Price Index (PPI) — Pharmaceutical Preparation Manufacturing (Index, Jun 1981=100)129 kỳ
- U.S. Consumer Price Index (CPI) — Medical Care Commodities / Prescription Drugs (Index, 1982–84=100)128 kỳ
- U.S. Consumer Price Index (CPI) — Medical Care Services (Index, 1982–84=100)128 kỳ
- U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. Retail Sales — Pharmacies and Drug Stores, Not Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. Real Personal Consumption Expenditures — Health Care (SAAR, $B Chained 2017 Dollars)42 kỳ
- DB Segment Context — Pharmaceutical Segment Revenue ($M) ($M)52 kỳ
- DB Geographic Context — Consolidated U.S. Revenue ($M) ($M)38 kỳ
- DB Income Statement — Consolidated Sales / Revenue ($M) ($M)69 kỳ
- DB Balance Sheet — Total Assets ($M) ($M)68 kỳ
- DB Cash Flow — Operating Cash Flow ($M) ($M)68 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Merck
- Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
- Form 10-K (filed 2026-02-24) ↗
- Organon & Co. SEC Filing (0001628280-26-051230) ↗
- Organon & Co. SEC Filing (0001628280-26-011125) ↗
- Form 10-Q (filed 2026-08-07) ↗
- Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
- Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
- Form 10-K (filed 2019-02-27) ↗
- Form 10-K (filed 2021-02-25) ↗
- Form 10-K (filed 2023-02-24) ↗
- Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
- Form 10-Q (filed 2021-05-05) ↗
See a number that looks wrong?